

## ECFS NEWSLETTER - Issue 55 - September 2017

01. Letter from the President
02. Annual General Meeting - Minutes
03. ECFS Board Elections
04. JCF Impact factor
05. Live webinar
06. Job Posting
07. PSA Study in children with CF in different European countries
08. ECFS Award
09. Upcoming Events
10. Deadlines
11. 2017 Seville - Free Registration Winners
12. Current References in CF

European Cystic Fibrosis Society  
Kastanieparken 7,  
7470 Karup, Denmark  
Tel: +45 86 676260  
Fax: +45 86 676290  
[info@ecfs.eu](mailto:info@ecfs.eu)  
[www.ecfs.eu](http://www.ecfs.eu)

### 01. Letter from the President

Dear Friends,

I hope this finds you well and that you all have had a chance to enjoy some relaxing summer vacation.

For those of you who participated in the June ECFS Conference in Seville, I am sure you will agree that it was a great success, and I would again like to thank the conference President Esther Quintana Gallego for her contribution to the event. I would also like to thank the local Cystic Fibrosis community and all the volunteers for their considerable and enthusiastic support. My sincere thanks go to the Scientific Committee who produced an excellent programme, and to the speakers, moderators and presenters for their superb contribution.

The ECFS continued its tradition of awarding grants to young researchers based on the merit of their submitted abstracts, and we were happy to support 20 young researchers with a Travel Grant. We also granted 3 Young Investigator Awards and were delighted to welcome the Young Investigator Awardees to the Closing Ceremony. All the award winners also received a 1 year free membership subscription to the ECFS.



Young Investigator Awards 2017:  
On the picture, Katharina Stauer (AT) on the right,  
Katie Farrant (UK) in the middle. Yanan Wang (AU)  
could not be present for the picture.

To honour the enormous contribution of Prof. Gerd Döring, the ECFS has initiated a Gerd Döring Award in 2015 that is given annually to honour an exceptional early career young European scientist. This award includes a monetary grant of € 5000 to support research.

This year, the Award was presented to Viola Camilla Scoffone (IT) for her manuscript entitled “Efflux-mediated resistance to a benzothiadiazol derivative effective against *Burkholderia cenocepacia*”, published in 2015 in *Frontiers in Microbiology*.

[More information on the ECFS Awards](#)



Once again, speakers at this year’s conference were asked to make their presentations (slides) available on the ECFS website (for members only) and these can be viewed by signing in under the “MY ECFS” tab on the homepage of our website [www.ecfs.eu](http://www.ecfs.eu).

This year in Seville, we also webcasted several sessions, amongst which the CF courses in English and Spanish, and we are working on making these available on the ECFS Education platform that will be launched shortly. We will keep you informed about the developments of our ECFS Education project.

Thanks go to all of you who participated to the Board elections. I would like to warmly congratulate Isabelle Fajac for her new position as President Elect. She will take over as ECFS President officially from the next Annual General Meeting at the Belgrade conference and I look forward to working closely with her over the coming months as I hand over the reins.

I take this opportunity to also congratulate Kevin Southern and Marcus Mall who are starting their second terms on the ECFS Board.

We are always pleased to see new initiatives and projects and I am happy to report that the ECFS Board recently approved two working groups: an international Working Group on anti microbial resistance together with the American CF Foundation, the Canadian CF Foundation and the Australian CF Association; and an ECFS Working Group on fungal pathogens led by Carsten Schwarz.

We are well into the planning for the Basic Science Conference which will be held in Loutraki, on the Gulf of Corinth in Greece (21-24 March 2018), and the annual conference which will be held 06-09 June 2018 in Belgrade, Serbia. Programmes for both conferences will be available soon and we hope that you will take an active part in these events and consider submitting your best work for presentation and discussion. The abstract submission deadline for the conference in Belgrade will be 19 January 2018. More information about the conferences can be found on our website.

I would like to thank those members who participated in this year’s Annual General Meeting in Seville, and you will find the minutes from the meeting included in this Newsletter.

As always, I would like to remind you to please feel free to send us articles that you would like to have included in forthcoming newsletters as this provides a great vehicle for communication.

Best wishes,

Kris De Boeck, ECFS President

## 02. Annual General Meeting Minutes

For the latest dates of ECFS activities and meetings please refer to Point 09: Upcoming events

### Minutes of the Annual General Meeting of the European Cystic Fibrosis Society

#### 40th European Cystic Fibrosis Conference, Seville, Spain, 9th June 2017

Presiding Officer: Prof. Kris De Boeck

The meeting was opened at 18.30.

Number of Participants: 64

#### President's Report

Prof. Kris De Boeck welcomed the ECFS members present and thanked them for their participation in the meeting. She hopes for higher number of participants at the AGM and invited all attendees to share a drink as a token of appreciation for their commitment to the ECFS.

She presented a slide listing the current ECFS Projects and Working Groups, and noted that reports on these activities had been provided ahead of the meeting and Coordinators of these projects would be ready to answer questions on their activities later on in the meeting.

Regarding ECFS conferences, she reported current figures of 2345 delegates registered for the Seville conference and a record number of 648 abstracts had been submitted. She announced more communication with the membership during the conference with the introduction of slideshows with important messages to the membership. She took the opportunity to thank the Conference President and all the other organizers for their contribution to a smooth preparation of the conference.

She went on to provide an overview of the ECFS activities this year, beginning with the Steering Committee meetings of the CTN and ECFSPR in January and the ECFS Diagnostic Network Working Group meeting in Ljubljana in February. She mentioned the highly successful Basic Science conference held in Albufeira, Portugal where a record number of abstract submissions were recorded.

The President then presented the programme of activities for 2017-2018 to include:

- ECFS Autumn Meeting, Indianapolis 1 November 2017
- CTN Steering Group Meeting, TBC 25-26 January 2018
- ECFS Winter Board Meeting, TBC 24 January 2018
- Registry Steering Group Meeting, TBC 26 January 2018
- ECFS Diagnostic Network WG Meeting, TBC February 2018
- 14<sup>th</sup> ECFS Basic Science Conference, TBC March 2018
- Young Investigators Meeting, Paris 21-23 February 2018
- 41<sup>st</sup> European CF Conference, Belgrade 6-9 June 2018

Prof. De Boeck presented the breadth of activities and plans ahead for the society.

- Continuing CFTR gene sequencing service with a goal to see 95% of patients with CF in every country to have 2 mutations identified by 2018
- ECFS mental health Working Group: the working group's focus is on the dissemination and implementation of mental health guidelines in Europe as well as the monitoring and evaluation of mental health screening. The working group's web pages on the ECFS website includes resources and links to translations of screening tools
- A strategic plan to maximize progress in CF therapies is being designed under the leadership of Jane Davies, London, UK. Documents related to Optimizing trial design, drug development for patients with rare *CFTR* mutations and speeding up access to successfully trialed drugs will be open for discussion

- Education: The ECFS Education project continues to expand and Prof De Boeck encouraged all to be generous with their slides and educational material and share with the wider CF community. An ECFS Education committee has been formed. The committee is chaired by Daniel Peckham and includes 1 representative of each ECFS Working group, Special Interest Group and project (standards of care, CTN, Registry). The aims of the committee are to work closely with members and support the development of a clear curriculum appropriate to each sub speciality. The committee will advise on existing educational resources to be referenced, assess unmet educational needs and support the development of educational modules.
- ECFS Book: the next ECFS book will be dedicated to infants and young children. The editors, Kevin Southern and Kris De Boeck have invited authors for the different chapters with a deadline of September for delivery of the chapters.

Prof. De Boeck presented some initiatives to further encourage participation of ECFS members to the activities of the Society.

- Board attendance at AGM
- ECFS Community bulletin boards (including job offers, collaborations asked and other announcements)
- Proposal box for ECFS members at the conference where suggestions for project opportunities and questions to ECFS board can be asked.
- Suggestions for tomorrow lounge activities
- Special interest groups associated with ECFS
- Social media
- Board elections on site: this year, elections were open until the day prior to the AGM. 152 members voted (electorate list included 819 members) and Prof De Boeck was disappointed only 10 members took advantage of the voting facility at the conference.

The audience was asked for any questions:

Silke van Koningsbruggen suggested having the election booth available at a central place, maybe in the conference registration area.

Daniel Peckham proposed to look into including the online voting on the ECFS app that will be developed.

Jaroslav Walkowiak noted that attendance to the AGM shows commitment to the ECFS and suggested the votes to take place at the AGM only.

### Secretary's Report

Prof. Harm Tiddens reported the preliminary membership numbers for 2017 (until May) were 986, an increase in comparison with the figures reported at the same time frame in 2016. One of the reasons for this was the introduction of conference registration and membership subscription available to all attendees.

In view of the healthy financial situation of the Society, he was happy to inform the membership that there would be no increase to the standard subscription fee in 2018; it will remain at Euro 120. There will be a continued lower rate for some categories of members who do not wish to receive the Journal of Cystic Fibrosis (JCF):

- Allied Health Professionals, PhD Students and Post Docs - 50 € (\*)
- Retired members still actively engaged in an ECFS Project or Working Group - Free (\*)
- Corporate membership rate for colleagues from the industry - 220 € (full membership benefits but no voting rights).

(\*) no JCF subscription associated with this rate

The discounted 3 years subscription (300 € instead of 360 €) introduced in 2015 will be offered as a membership possibility for the years 2018-2019-2020

He communicated the results of the recent elections and was happy to announce the election of Prof. Isabelle Fajac as President Elect. The Board members elected are: Marcus Mall and Kevin Southern, who have been elected for a second term.

The audience was asked for any questions:

Vincent Gulmans asked about the possibility of granting voting rights to ECFS members affiliated with patient organizations.

- This was recently discussed at an ECFS Board meeting and the request was not approved but the topic can be further discussed.

### Treasurer's Report

Prof. Harm Tiddens presented the audited ECFS Financial statement for the year 2016. The result of the year was very favourable, with a surplus of € 330,131 resulting in a positive balance for the Society's net assets of € 2,906,334 at 31st December 2016. Prof. Tiddens informed the AGM that the full audited accounts will be posted on the website.

### Update on Journal of Cystic Fibrosis

Prof. Scott Bell reported on developments of JCF. There were 409 submissions and 119 Original Research Articles and Reviews published in 2016.

There has been a steady increase in the number of Science Direct downloads (over 500,000).

New initiatives and recent changes include:

- Editorial board: retiring members are Margarida Amaral, Garry Cutting, Sue Wolfe. Suzannah King is newly appointed as editor
- Lancet respiratory Medicine / JCF partnership: papers found more suitable to JCF than LRM sent to JCF
- Joint LRM/JCF symposium at conference: successful in Basel 2016 and Seville 2017
- Supplements: CFF Nutrition guidelines being submitted - ECFS Basic Science conference 2017 (mini reviews of symposia topics)
- CF Research News: high level of commitment (only 9/213 did not provide lay summary) ; 2016 - n=84

Finally, Prof Bell showed a slide with the Top Cites from the start of JCF. He encouraged guidelines to be published in JCF.

### Report from ECFS CTN

Dr. Tim Lee presented a graph demonstrating the progression of studies conducted by the CTN since 2009. He also presented the evolution of the CTN services including number of protocols reviewed and number of feasibility checks performed. He reported 6 Protocol Reviews ongoing as of June 2017 and 3 Feasibilities finalized May 2017 as well as 7 ongoing or in setup.

He presented the ECFS CTN sites activity in 2016 with a median of 6 studies per site and a median 7% enrolment. He reported on the implementation of the Additional Research Capacity Award during 2017 to sites that had identified this as a significant barrier and met selection criteria.

All CTN sites have received detailed weighted quality reports and metrics and low performing sites will be offered the possibility to enter a coaching programme before reapplying to be part of the CTN.

He announced a new ECFS CTN expansion for 2019 with applications open in the fall 2018.

Finally, he thanked the CTN team and all those committed in the different CTN committees for their hard work and dedication to the success of the CTN.

### Report from ECFS Standards of Care

Dr. Pavel Drevinek reported on the progress of the Standards of Care project.

The best practice subgroup is reviewing and updating the 2014 Standards of Care. The document is to be reviewed by the ECFS Board before publication as open access.

The Quality Management subgroup is finalising a quality management module for the Education platform. A module for benchmarking across countries/centres is being developed in the ECFSTracker.

A successful Standards of Care symposium was held at the Seville conference with simultaneous translation in Spanish available.

The Standards of Care next steps will be looking at accreditation of CF centres or auditing of CF centres.

Finally, Dr. Drevinek thanked Prof Martin Stern for his help and commitment to the Registry and Standards of Care Quality management group over the years.

### Report from ECFS Patient Registry

Dr. Luz Naehrlich reported on the activities of the ECFS Patient Registry (ECFSPR).

The ECFSPR is expanding its coverage with 31 countries participating and over 42,000 CF patients.

He reported on the different ECFSPR groups:

- the Data Quality Group with aim to ensure accuracy and quality of data
- the Definitions Group focuses on reviewing variables and definitions
- the Global CF harmonisation project aims to harmonise variables & definitions to allow comparison worldwide
- the Pharmacovigilance project is currently developing a procedure with EMA
- the Patient awareness project develops at a glance report, Posters in cooperation with CF Europe to bring data closer to patients

Finally, Dr Naehrlich thanked Dr. McKone for his leadership of the ECFSPR over the last 3 years.

### Reports from ECFS Working Groups

Prior to the Annual General Meeting, members had been sent the progress reports from the ECFS Working Groups.

Current Working Groups:

Diagnostics Network Working Group

Exercise Working Group

Neonatal Screening Working Group

Cystic Fibrosis Molecular & Cell Biology and Physiology Basic Science Working Group

Mental Health Working Group

The audience was asked for any questions: None received.

### Special Interest Groups

Prof De Boeck reported on Special Interest Groups and their affiliation with ECFS:

ECFS affiliated:

ECFS Nursing Special interest Group (ECFS NSiG)

European Cystic Fibrosis Pharmacy Group (ECFPG)

ECFS Psychosocial Working Group

European Cystic Fibrosis Nutrition Group

not ECFS affiliated:

International Physiotherapy Group for Cystic Fibrosis

### Annual Conference 2018

A slide was shown presenting the 41st ECFS conference, to be held in Belgrade, Serbia, 6-9 June 2018.

Questions/Comments received: None

### Any Other Business

None

With no further items being raised, the meeting ended at 19.30.


### 03. ECFS Board elections



Isabelle Fajac (FR) | Marcus Mall (DE) | | Kevin Southern (UK) )

We held Board elections in June. We are happy to announce that Prof. Isabelle Fajac has been elected as ECFS President Elect and will become President of the ECFS at the AGM in June 2018. Prof. Marcus Mall and Prof. Kevin Southern have been elected as Board Members for a second term.

### 04. JCF Impact factor



The official 2016 Impact Factors (IF) were released in July, and the Journal of Cystic Fibrosis (JCF) has increased its IF from a 2015 IF of 3.853 to 4.727. JCF ranks 8th of 59 in the Respiratory System category.

The Journal Impact Factor is published each year by Thomson Reuters. It is a measure of the number of times an average paper in a particular journal is cited during the preceding two years.

JCF has continued to work hard for this achievement, through thoughtful structuring of its editorial pages and continuing growth in our international presence. The ECFS would like to thank the Editor in Chief, Prof. Scott Bell, and the Editorial Board. Their excellent service and work have helped JCF gain its current standings and continue to aid its growth.

### 05. Aerosolized Agents for Airway Clearance in Cystic Fibrosis: When, How and Why? Live webinar

A free live webinar from the Elsevier Office of Continuing Medical Education will be organised on 02 October 2017, at 22:00 CET | 21:00 BST | 16:00 EDT - Tuesday 3 October 2017 at 7:00AM AEDT.

This live webinar is a roundtable discussion between three international expert faculty in cystic fibrosis (CF). This expert faculty will discuss the role of aerosolized agents for improving airway clearance, including caveats from their own extensive clinical experience in managing patients with this condition. The faculty will also deliberate on strategies to improve patient adherence to aerosolized CF therapies in a case study based format. The discussions at the webinar will support participants in clinical decision making as well as in helping their patients achieve optimal benefit through adherence to their aerosolized therapies for airway clearance in CF.

#### FACULTY

Chair: Professor John P. Clancy, MD

Faculty: Professor Kevin W. Southern, MBChB, MRCP, FRCPCH, PhD

Professor Sarath Ranganathan, MBChB, MRCP, FRCPCH, FRACP, PhD

[More information](#)

## 06. Job postings



As from 01 January 2018, a Post-doctoral Position will be available at the Department of Cell Physiology and Metabolism of the Geneva Medical Faculty.  
Contact person: Dr. Marc Chanson

Deadline for applications: 15 October 2017  
[Detailed offer](#)

## 07. Questionnaire: The treatment “in real life” of first detected PSA in children with CF in different European countries.

Under supervision of Prof Dr. M. Ballmann, Isabell Weber from Rostock University Medical Center is conducting a Europe-wide comparison on the eradication of first proven *Pseudomonas aeruginosa* (PSA) infection in children with cystic fibrosis.

With this questionnaire, her objective is to compare the treatment “in real life” of first detected PSA in children with CF in different European countries.

The questionnaire can be completed online with the link below. You will need a password: **psa2017**

<https://evasys.uni-rostock.de/evasys/online.php?p=psa2017>

Should you prefer to use a **paper version**, please print out the pdf- file via the link below and fax it when filled to **+49 381 494 7028**.

You can find more information hereunder:

[Description of the study](#)

[Questionnaire](#)

## 08. ECFS Award - Dr. Jeffrey Beekman

In Seville, we were happy to hand over the ECFS Award to Dr. Jeffrey Beekman. This award acknowledges Dr Beekman’s remarkable contribution to cystic fibrosis, initiating a breakthrough in the field by developing a functional CFTR assay in the CF intestinal organoid model developed in Utrecht. This has brought major advances to the field of this orphan disease, not only for developing and evaluating therapies in the context of personalized medicine, but also for diagnostic purposes and beyond.

2017 is definitely a great year for Dr Beekman as he also received the Excellence Award from the European Respiratory Society in Milan earlier this month.

Once again we extend our congratulations!



## 09. Upcoming Events



### Indianapolis, IN, US

01 November 2017:

ECFS Board Meeting

02-04 November 2017:

32<sup>nd</sup> North American Cystic Fibrosis Conference

### Brussels, Belgium

24 January 2018:

ECFS Winter Board Meeting

25 January 2018:

ECFS Standards of Care Meeting

25-26 January 2018:

ECFS CTN Steering Group Meeting

ECFS Patient Registry Steering Group Meeting

### St Gallen, Switzerland:

08-10 February 2018

ECFS Diagnostic Network Working Group Meeting

### Paris, France

21-23-February 2018

12<sup>th</sup> European Young Investigators Meeting

### Loutraki, Greece

21-24 March 2018

ECFS 15<sup>th</sup> Basic Science Conference

### Belgrade, Serbia

05 June 2018:

ECFS Board Meeting

06-09 June 2018:

41<sup>st</sup> European CF Conference

## 10. Deadlines

- Abstract submission Young Investigator Meeting	01	November	2017
- Abstract submission 15th ECFS Basic Science conference	12	January	2018
- Abstract submission ECFS Conference Belgrade	19	January	2018
- Nomination ECFS Award	15	February	2018
- Nomination Gerd Döring Award	15	February	2018
- Nomination ECFS Elections	30	March	2018



## 11. 2017 Seville Conference Survey - Free Registration Winners



The ECFS would like to thank all those who took the time to answer the ECFS 2017 Survey after the conference in Seville. The answers and comments help us to keep on improving our conferences.

As announced, three free registrations to the next ECFS Conference in Belgrade were selected from the respondents.

We congratulate the winners:

- Sabina Wiecek, Katowice, Poland
- Kay Ramsay, Brisbane, Australia
- Darren Sills, Nottingham, United Kingdom

## 12. Current references in CF

Please scroll to next page for full list.

## CF Reference List

### Adults & Adolescents

- Coyne I., Sheehan AM., Heery E., While AE.  
Improving transition to adult healthcare for young people with cystic fibrosis: A systematic review  
*Journal of Child Health Care* 2017; 21: 312 - 330
- Faint NR., Staton JM., Stick SM., Foster JM., Schultz A.  
Investigating self-efficacy, disease knowledge and adherence to treatment in adolescents with cystic fibrosis  
*Journal of Paediatrics and Child Health* 2017; 53: 488 - 493
- Kopciuch D., Zaprutko T., Paczkowska A., Nowakowska E.  
Costs of treatment of adult patients with cystic fibrosis in Poland and internationally  
*Public Health* 2017; 148: 49 - 55
- Kopp AT., Chini BA., Dimitriou SM., Grosseohme DH.  
Body Sanctification and Sleep in Adolescents with Cystic Fibrosis: A Pilot Study  
*Journal of Religion & Health* 2017; 56: 1837 - 1845
- Patel A., Dowell M., Giles BL.  
Current Concepts of Transition of Care in Cystic Fibrosis  
*Pediatric Annals* 2017; 46: E188 - E192
- Zacharasiewicz A., Renner S., Haderer F., Weber M., Dehlink E., Szeffalusi Z., Frischer T.  
Early detection of lung function decrements in children and adolescents with cystic fibrosis using new reference values  
*Wiener Klinische Wochenschrift* 2017; 129: 533 - 539

### Animal Model

- Harada Y., Iizuka S., Saegusa Y., Mogami S., Fujitsuka N., Hattori T.  
Mashinigan Improves Opioid-Induced Constipation in Rats by Activating Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel  
*Journal of Pharmacology and Experimental Therapeutics* 2017; 362: 78 - 84
- Paemka L., McCullagh BN., Abou Alaiwa MH., Stoltz DA., Dong Q., Randak CO., Gray RD., McCray PB.  
Monocyte derived macrophages from CF pigs exhibit increased inflammatory responses at birth  
*Journal of Cystic Fibrosis* 2017; 16: 471 - 474
- Rymut SM., Corey DA., Valerio DM., Erokwu BO., Flask CA., Kelley TJ., Hodges CA.  
Improved growth patterns in cystic fibrosis mice after loss of histone deacetylase 6  
*Scientific Reports* 2017; 7: ArNo: 3676

### Antimicrobials

- Ahmed MU., Velkov T., Lin YW., Yun B., Nowell CJ., Zhou FF., Zhou QT., Chan K., Azad MAK., Li J.  
Potential Toxicity of Polymyxins in Human Lung Epithelial Cells  
*Antimicrobial Agents and Chemotherapy* 2017; 61: e02690-16
- Akdag Cayli YA., Sahin S., Buttini F., Balducci AG., Montanari S., Vural I., Oner L.  
Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients  
*Drug Development and Industrial Pharmacy* 2017; 43: 1378 - 1389
- Aziz DB., Low JL., Wu ML., Gengenbacher M., Teo JWP., Dartois V., Dick T.  
Rifabutin Is Active against Mycobacterium abscessus Complex

- Antimicrobial Agents and Chemotherapy* 2017; 61: e00155-17
- Belfield K., Bayston R., Hajduk N., Levell G., Birchall JP., Daniel M.  
Evaluation of combinations of putative anti-biofilm agents and antibiotics to eradicate biofilms of *Staphylococcus aureus* and *Pseudomonas aeruginosa*  
*Journal of Antimicrobial Chemotherapy* 2017; 72: 2531 - 2538
- Bernardes EV., Charron-Mazenod L., Reading DJ., Reckseidler-Zenteno SL., Lewenza S.  
Exopolysaccharide-Repressing Small Molecules with Antibiofilm and Antivirulence Activity against *Pseudomonas aeruginosa*  
*Antimicrobial Agents and Chemotherapy* 2017; 61: e01997-16
- Boisson M., Gregoire N., Cormier M., Gobin P., Marchand S., Couet W., Mimos O.  
Pharmacokinetics of nebulized colistin methanesulfonate in critically ill patients  
*Journal of Antimicrobial Chemotherapy* 2017; 72: 2607 - 2612
- Buchs C., Dalphin ML., Sanchez S., Perceval M., Coutier L., Mainguy C., Kassai-Koupai B., Reix P.  
Palivizumab prophylaxis in infants with cystic fibrosis does not delay first isolation of *Pseudomonas aeruginosa* or *Staphylococcus aureus*  
*European Journal of Pediatrics* 2017; 176: 891 - 897
- Castillo-Juarez I., Lopez-Jacome LE., Soberon-Chavez G., Tomas M., Lee JT., Castaneda-Tamez P., Hernandez-Barragan IA., Cruz-Muniz MY., Maeda T., Wood TK., Garcia-Contreras R.  
Exploiting Quorum Sensing Inhibition for the Control of *Pseudomonas aeruginosa* and *Acinetobacter baumannii* Biofilms  
*Current Topics in Medicinal Chemistry* 2017; 17: 1915 - 1927
- Caumo DTM., Geyer LB., Teixeira AR., Barreto SSM.  
Hearing thresholds at high frequency in patients with cystic fibrosis: a systematic review  
*Brazilian Journal of Otorhinolaryngology* 2017; 83: 464 - 474
- Cossio-Ayala M., Domiguez-Lopez M., Mendez-Enriquez E., Portillo-Tellez MD., Garcia-Hernandez E.  
In vitro and in vivo antimicrobial activity of a synthetic peptide derived from the C-terminal region of human chemokine CCL13 against *Pseudomonas aeruginosa*  
*Peptides* 2017; 94: 49 - 55
- DaCosta A., Jordan CL., Giddings O., Lin FC., Gilligan P., Esther CR.  
Outcomes associated with antibiotic regimens for treatment of *Mycobacterium abscessus* in cystic fibrosis patients  
*Journal of Cystic Fibrosis* 2017; 16: 483 - 487
- De Cock PAJG., van Dijkman SC., de Jaeger A., Willems J., Carlier M., Verstraete AG., Delanghe JR., Robays H., Vande Walle J., Della Pasqua OE., De Paepe P.  
Dose optimization of piperacillin/tazobactam in critically ill children  
*Journal of Antimicrobial Chemotherapy* 2017; 72: 2002 - 2011
- Garinis AC., Cross CP., Srikanth P., Carroll K., Feeney MP., Keefe DH., Hunter LL., Putterman DB., Cohen DM., Gold JA., Steyger PS.  
The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis  
*Journal of Cystic Fibrosis* 2017; 16: 401 - 409

- Greenwood J., Schwarz C., Sommerwerck U., Nash EF., Tamm M., Cao WH., Mastoridis P., Debonnett L., Hamed K.  
Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary *Pseudomonas aeruginosa* infection  
*Therapeutic Advances in Respiratory Disease* 2017; 11: 249 - 260
- Gruber M., Moser I., Nagl M., Lackner M.  
Bactericidal and Fungicidal Activity of N-Chlorotaurine Is Enhanced in Cystic Fibrosis Sputum Medium  
*Antimicrobial Agents and Chemotherapy* 2017; 61: 5:e02527-16
- Handelsman JA., Nasr SZ., Pitts C., King WM.  
Prevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides  
*Pediatric Pulmonology* 2017; 52: 1157 - 1162
- Howlin RP., Cathie K., Hall-Stoodley L., Cornelius V., Duignan C., Allan RN., Fernandez BO., Barraud N., Bruce KD., Jefferies J., Kelso M., Kjelleberg S., Rice SA., Rogers GB., Pink S., Smith C., Sukhtankar PS., Salib R., Legg J., et al  
Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic *Pseudomonas aeruginosa* Infection in Cystic Fibrosis  
*Molecular Therapy* 2017; 25: 2104 - 2116
- LeCleir LK., Pettit RS.  
Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients  
*Pediatric Pulmonology* 2017; 52: 1000 - 1005
- Lendermon EA., Coon TA., Bednash JS., Weathington NM., McDyer JF., Mallampalli RK.  
Azithromycin decreases NALP3 mRNA stability in monocytes to limit inflammasome-dependent inflammation  
*Respiratory Research* 2017; 18: ArNo: 131
- Lexmond AJ., Hagedoorn P., Frijlink HW., Rottier BL., de Boer AH.  
Prerequisites for a dry powder inhaler for children with cystic fibrosis  
*PLoS One* 2017; 12: 8:e0183130
- Mardirossian M., Pompilio A., Degasperis M., Runti G., Pacor S., Di Bonaventura G., Scocchi M.  
D-BMAP18 Antimicrobial Peptide Is Active In vitro, Resists to Pulmonary Proteases but Loses Its Activity in a Murine Model of *Pseudomonas aeruginosa* Lung Infection  
*Frontiers in Chemistry* 2017; 5: ArNo: 40
- Maselli DJ., Keyt H., Restrepo MI.  
Inhaled Antibiotic Therapy in Chronic Respiratory Diseases  
*International Journal of Molecular Sciences* 2017; 18: 5:1062
- Mashat M., Clark BJ., Assi KH., Chrystyn H.  
Assessment of recent nebulizer delivery systems using urinary pharmacokinetics method and aerodynamic characteristics of TOBI (R) nebulized dose following inhalation  
*Journal of Drug Delivery Science and Technology* 2017; 39: 428 - 434
- Mazer DM., Young C., Kalikin LM., Spilker T., LiPuma JJ.  
In Vitro Activity of Ceftolozane-Tazobactam and Other Antimicrobial Agents against *Burkholderia cepacia* Complex and *Burkholderia gladioli*  
*Antimicrobial Agents and Chemotherapy* 2017; 61: 9:e00766-17
- Murakami K., Ono T., Viducic D., Somiya Y., Kariyama R., Hori K., Amoh T., Hirota K., Kumon H., Parsek MR., Miyake Y.  
Role of psl Genes in Antibiotic Tolerance of Adherent *Pseudomonas aeruginosa*  
*Antimicrobial Agents and Chemotherapy* 2017; 61: 7:e02587-16
- Mustafa MH., Khandekar S., Tunney MM., Elborn JS., Kahl BC., Denis O., Plesiat P., Traore H., Tulkens PM., Vanderbist F., Van Bambeke F.  
Acquired resistance to macrolides in *Pseudomonas aeruginosa* from cystic fibrosis patients  
*European Respiratory Journal* 2017; 49: 5:1601847
- Narayanaswamy VP., Giatpaiboon S., Baker SM., Wiesmann WP., LiPuma JJ., Townsend SM.  
Novel glycopolymer sensitizes *Burkholderia cepacia* complex isolates from cystic fibrosis patients to tobramycin and meropenem  
*PLoS One* 2017; 12: 6:e0179776
- Nichols DP., Happoldt CL., Bratcher PE., Caceres SM., Chmiel JF., Malcolm KC., Saavedra MT., Saiman L., Taylor-Cousar JL., Nick JA.  
Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis  
*Journal of Cystic Fibrosis* 2017; 16: 358 - 366
- Olivares E., Badel-Berchoux S., Provot C., Jaulhac B., Prevost G., Bernardi T., Jehl F.  
Tobramycin and Amikacin Delay Adhesion and Microcolony Formation in *Pseudomonas aeruginosa* Cystic Fibrosis Isolates  
*Frontiers in Microbiology* 2017; 8: ArNo: 1289
- Olveira C., Padilla A., Dorado A., Contreras V., Garcia-Fuentes E., Rubio-Martin E., Porras N., Dona E., Carmona A., Olveira G.  
Inflammation and Oxidation Biomarkers in Patients with Cystic Fibrosis: The Influence of Azithromycin  
*Eurasian Journal of Medicine* 2017; 49: 118 - 123
- Panguluri S., Gunda P., Debonnett L., Hamed K.  
Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary *Pseudomonas aeruginosa* Infection in Patients with Cystic Fibrosis  
*Clinical Drug Investigation* 2017; 37: 795 - 805
- Papp-Wallace KM., Becka SA., Zeiser ET., Ohuchi N., Mojica MF., Gatta JA., Falleni M., Tosi D., Borghi E., Winkler ML., Wilson BM., LiPuma JJ., Nukaga M., Bonomo RA.  
Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for *Burkholderia cepacia* Complex Isolates from Cystic Fibrosis Patients  
*ACS Infectious Diseases* 2017; 3: 502 - 511
- Ramanathan B., Jindal HM., Le CF., Gudimella R., Anwar A., Razali R., Poole-Johnson J., Manikam R., Sekaran SD.  
Next generation sequencing reveals the antibiotic resistant variants in the genome of *Pseudomonas aeruginosa*  
*PLoS One* 2017; 12: 8:e0182524
- Rello J., Sole-Lleonart C., Rouby JJ., Chastre J., Blot S., Poulakou G., Luyt CE., Riera J., Palmer LB., Pereira JM., Felton T., Dhanani J., Bassetti M., Welte T., Roberts JA.  
Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases  
*Clinical Microbiology and Infection* 2017; 23: 629 - 639
- Sans-Serramitjana U., Jorba M., Pedraz JL., Vinuesa T., Vinas M.  
Determination of the spatiotemporal dependence of *Pseudomonas aeruginosa* biofilm viability after treatment with NLC- colistin  
*International Journal of Nanomedicine* 2017; 12: 4409 - 4413
- Sierra JM., Fuste E., Rabanal F., Vinuesa T., Vinas M.  
An overview of antimicrobial peptides and the latest advances in their development  
*Expert Opinion on Biological Therapy* 2017; 17: 663 - 676

**Smyth AR., Bhatt J., Nevitt SJ.**  
Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2017; : 3:CD002009

**Smyth AR., Rosenfeld M.**  
Prophylactic anti-staphylococcal antibiotics for cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2017; : 4:CD001912

**Tan JH., Vidailiac C., Yam JKH., Chua SL., Givskov M., Yang L.**  
In Vitro and In Vivo Efficacy of an LpxC Inhibitor, CHIR-090, Alone or Combined with Colistin against *Pseudomonas aeruginosa* Biofilm  
*Antimicrobial Agents and Chemotherapy* 2017; 61: 7:e02223-16

**Torge A., Wagner S., Chaves PS., Oliveira EG., Guterres SS., Pohlmann AR., Titz A., Schneider M., Beck RCR.**  
Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis  
*International Journal of Pharmaceutics* 2017; 527: 92 - 102

**Trang TP., Hanretty AM., Langelier C., Yang K.**  
Use of isavuconazole in a patient with voriconazole-induced QTc prolongation  
*Transplant Infectious Disease* 2017; 19: 4:e12712

**Tureli NG., Torge A., Juntke J., Schwarz BC., Schneider-Daum N., Tureli AE., Lehr CM., Schneider M.**  
Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis *Pseudomonas aeruginosa* lung infections  
*European Journal of Pharmaceutics and Biopharmaceutics* 2017; 117: 363 - 371

**Velikova N., Wells JM.**  
Rationale and Prospects of Targeting Bacterial Two-component Systems for Antibacterial Treatment of Cystic Fibrosis Patients  
*Current Drug Targets* 2017; 18: 687 - 695

**Waters V., Ratjen F.**  
Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of *Pseudomonas aeruginosa* in cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2017; : 6:CD006961

**Waters V., Yau Y., Beaudoin T., Wettlaufer J., Tom SK., McDonald N., Rizvi L., Klingel M., Ratjen F., Tullis E.**  
Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic *Burkholderia cepacia* complex infection  
*Journal of Cystic Fibrosis* 2017; 16: 492 - 495

**Zobell JT., Epps KL., Young DC.**  
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins update  
*Pediatric Pulmonology* 2017; 52: 863 - 865

## Cardiology

**Sayyid ZN., Sellers ZM.**  
Technological advances shed light on left ventricular cardiac disturbances in cystic fibrosis  
*Journal of Cystic Fibrosis* 2017; 16: 454 - 464

## Cell Biology

**Biswas R., Kumar P., Pollard HB.**  
Regulation of mRNA turnover in cystic fibrosis lung disease  
*Wiley Interdisciplinary Reviews-rna* 2017; 8: 4:UNSP e1408

**Guerra L., D'Oria S., Favia M., Castellani S., Santostasi T., Polizzi AM., Mariggio MA., Gallo C., Casavola V., Montemurro P., Leonetti G., Manca A., Conese M.**  
CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy  
*Pediatric Pulmonology* 2017; 52: 900 - 908

**Lampronti I., Dehecchi MC., Rimessi A., Bezzerri V., Nicolis E., Guerrini A., Tacchini M., Tamanini A., Munari S., D'Aversa E., Santangelo A., Lippi G., Sacchetti G., Pinton P., Gambari R., Agostini M., Cabrini G.**  
beta-Sitosterol Reduces the Expression of Chemotactic Cytokine Genes in Cystic Fibrosis Bronchial Epithelial Cells  
*Frontiers in Pharmacology* 2017; 8: ArNo: 236

**Macedo AN., Mathiapparanam S., Brick L., Keenan K., Gonska T., Pedder L., Hill S., Britz-McKibbin P.**  
The Sweat Metabolome of Screen-Positive Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport  
*ACS Central Science* 2017; 3: 904 - 913

**Sailland J., Grosche A., Baumlin N., Dennis JS., Schmid A., Krick S., Salathe M.**  
Role of Smad3 and p38 Signalling in Cigarette Smoke-induced CFTR and BK dysfunction in Primary Human Bronchial Airway Epithelial Cells  
*Scientific Reports* 2017; 7: ArNo: 10506

## CFTR

**Ahsan MK., Tchernychev B., Kessler MM., Solinga RM., Arthur D., Linde Cl., Silos-Santiago I., Hannig G., Ameen NA.**  
Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine  
*Physiological Reports* 2017; 5: 11:e13299

**Bagdany M., Veit G., Fukuda R., Avramescu RG., Okiyoneda T., Baaklini I., Singh J., Sovak G., Xu HJ., Apaja PM., Sattin S., Beitel LK., Roldan A., Colombo G., Balch W., Young JC., Lukacs GL.**  
Chaperones rescue the energetic landscape of mutant CFTR at single molecule and in cell  
*Nature Communications* 2017; 8: ArNo: 398

**Bergougnoux A., Petit A., Knabe L., Bribes E., Chiron R., De Sario A., Claustres M., Molinari N., Vachier I., Taulan-Cadars M., Bourdin A.**  
The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis  
*International Journal of Biochemistry & Cell Biology* 2017; 88: 124 - 132

**Bertrand CA., Mitra S., Mishra SK., Wang XH., Zhao Y., Pilewski JM., Madden DR., Frizzell RA.**  
The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9  
*American Journal of Physiology-lung Cellular and Molecular Physiology* 2017; 312: L912 - L925

**Bodas M., Silverberg D., Walworth K., Brucia K., Vij N.**  
Augmentation of S-Nitrosoglutathione Controls Cigarette Smoke-Induced Inflammatory-Oxidative Stress and Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis by Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function  
*Antioxidants & Redox Signaling* 2017; 27: 433 - 451

**Bossmann M., Ackermann BW., Thome UH., Laube M.**  
Signaling Cascade Involved in Rapid Stimulation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) by Dexamethasone  
*International Journal of Molecular Sciences* 2017; 18: 8:1807

- Castellani C., Tridello G., Tamanini A., Assael BM. Sweat chloride and immunoreactive trypsinogen in infants carrying two CFTR mutations and not affected by cystic fibrosis  
*Archives of Disease in Childhood* 2017; 102: 644 - 646
- Das J., Aleksandrov AA., Cui LY., He LH., Riordan JR., Dokholyan NV. Transmembrane helical interactions in the CFTR channel pore  
*Plos Computational Biology* 2017; 13: 6:e1005594
- Di Pietro C., Zhang PX., O'Rourke TK., Murray TS., Wang L., Britto CJ., Koff JL., Krause DS., Egan ME., Bruscia EM. Ezrin links CFTR to TLR4 signaling to orchestrate anti-bacterial immune response in macrophages  
*Scientific Reports* 2017; 7: ArNo: 10882
- Goncalves C., Gomez JP., Meme W., Rasolonjatovo B., Gosset D., Nedellec S., Hulin P., Huin C., Le Gall T., Montier T., Lehn P., Pichon C., Guegan P., Cheradame H., Midoux P. Curcumin/poly(2-methyl-2-oxazoline-b-tetrahydrofuran-b-2-methyl-2-oxazoline) formulation: An improved penetration and biological effect of curcumin in F508del-CFTR cell lines  
*European Journal of Pharmaceutics and Biopharmaceutics* 2017; 117: 168 - 181
- Hanukoglu I., Boggula VR., Vakhine H., Sharma S., Kleyman T., Hanukoglu A. Expression of epithelial sodium channel (ENaC) and CFTR in the human epidermis and epidermal appendages  
*Histochemistry and Cell Biology* 2017; 147: 733 - 748
- Hisert KB., Heltshe SL., Pope C., Jorth P., Wu X., Edwards RM., Radey M., Accurso FJ., Wolter DJ., Cooke G., Adam RJ., Carter S., Grogan B., Launsbach JL., Donnelly SC., Gallagher CG., Bruce JE., Stoltz DA., Welsh MJ., Hoffman LR. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections  
*American Journal of Respiratory and Critical Care Medicine* 2017; 195: 1617 - 1628
- Hudson RP., Dawson JE., Chong PA., Yang ZR., Millen L., Thomas PJ., Brouillette CG., Forman-Kay JD. Direct Binding of the Corrector VX-809 to Human CFTR NBD1: Evidence of an Allosteric Coupling between the Binding Site and the NBD1:CL4 Interface  
*Molecular Pharmacology* 2017; 92: 124 - 135
- Ideozu JE., Zhang X., Pan A., Ashrafi Z., Woods KJ., Hessner MJ., Simpson P., Levy H. Increased Expression of Plasma-Induced ABCC1 mRNA in Cystic Fibrosis  
*International Journal of Molecular Sciences* 2017; 18: 8:1752
- Kumari V., Desai S., Ameen NA. AP2 alpha modulates cystic fibrosis transmembrane conductance regulator function in the human intestine  
*Journal of Cystic Fibrosis* 2017; 16: 327 - 334
- Lago JEF., Cayarga AA., Gonzalez YJG., Mesa TC. A simple, fast and inexpensive method for mutation scanning of CFTR gene  
*BMC Medical Genetics* 2017; 18: ArNo: 58
- Li ZZ., Shen Z., Xue HP., Cheng S., Ji Q., Liu YT., Yang XJ. CFTR protects against vascular inflammation and atherogenesis in apolipoprotein E-deficient mice  
*Bioscience Reports* 2017; 37: ArNo: BSR20170
- Liang F., Shang HB., Jordan NJ., Wong E., Mercadante D., Saltz J., Mahiou J., Bihler HJ., Mense M. High-Throughput Screening for Readthrough Modulators of CFTR PTC Mutations  
*SLAS Technology* 2017; 22: 315 - 324
- Liu Y., Xu J., Xu LL., Wu TY., Sun YX., Lee YW., Wang B., Chan HC., Jiang XH., Zhang JF., Li G. Cystic fibrosis transmembrane conductance regulator mediates tenogenic differentiation of tendon-derived stem cells and tendon repair: accelerating tendon injury healing by intervening in its downstream signaling  
*FASEB Journal* 2017; 31: 3800 - 3815
- Loo TW., Clarke DM. Corrector VX-809 promotes interactions between cytoplasmic loop one and the first nucleotide-binding domain of CFTR  
*Biochemical Pharmacology* 2017; 136: 24 - 31
- Lopes-Pacheco M., Boinot C., Sabirzhanova I., Rapino D., Cebotaru L. Combination of Correctors Rescues CFTR Transmembrane-Domain Mutants by Mitigating their Interactions with Proteostasis  
*Cellular Physiology and Biochemistry* 2017; 41: 2194 - 2210
- Lucarelli M., Porcaro L., Biffignandi A., Costantino L., Giannone V., Albert L., Bruno SM., Corbetta C., Torresani E., Colombo C., Seia M. A New Targeted CFTR Mutation Panel Based on Next-Generation Sequencing Technology  
*Journal of Molecular Diagnostics* 2017; 19: 788 - 800
- Marunaka Y. The Mechanistic Links between Insulin and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Cl- Channel  
*International Journal of Molecular Sciences* 2017; 18: 8:1767
- Molina SA., Moriarty HK., Infield DT., Imhoff BR., Vance RJ., Kim AH., Hansen JM., Hunt WR., Koval M., McCarty NA. Insulin signaling via the PI3-kinase/Akt pathway regulates airway glucose uptake and barrier function in a CFTR-dependent manner  
*American Journal of Physiology-lung Cellular and Molecular Physiology* 2017; 312: 1688 - 1702
- Perniss A., Preiss K., Nier M., Althaus M. Hydrogen sulfide stimulates CFTR in Xenopus oocytes by activation of the cAMP/PKA signalling axis  
*Scientific Reports* 2017; 7: ArNo: 3517
- Reilly R., Mroz MS., Dempsey E., Wynne K., Keely SJ., McKone EF., Hiebel C., Behl C., Coppinger JA. Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis  
*Scientific Reports* 2017; 7: ArNo: 7642
- Sanz DJ., Hollywood JA., Scallan MF., Harrison PT. Cas9/gRNA targeted excision of cystic fibrosis-causing deep-intronic splicing mutations restores normal splicing of CFTR mRNA  
*PLoS One* 2017; 12: 9:e0184009
- Stauffer BB., Cui G., Cottrill KA., Infield DT., McCarty NA. Bacterial Sphingomyelinase is a State-Dependent Inhibitor of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR)  
*Scientific Reports* 2017; 7: ArNo: 2931
- Talwalkar JS., Koff JL., Lee HB., Britto CJ., Mulenon AM., Georgiopoulos AM. Cystic Fibrosis Transmembrane Regulator Modulators: Implications for the Management of Depression and Anxiety in Cystic Fibrosis  
*Psychosomatics* 2017; 58: 343 - 354
- VanDevanter DR., Mayer-Hamblett N., Boyle M. Feasibility of placebo-controlled trial designs for new CFTR modulator evaluation  
*Journal of Cystic Fibrosis* 2017; 16: 496 - 498
- Vernon RM., Chong PA., Lin H., Yang ZR., Zhou QX., Aleksandrov AA., Dawson JE., Riordan JR., Brouillette CG., Thibodeau PH., Forman-Kay JD. Stabilization of a nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator yields insight into disease-causing mutations  
*Journal of Biological Chemistry* 2017; 292: 14147 - 14164

**Wang GY.**  
Mechanistic insight into the heme-independent interplay between iron and carbon monoxide in CFTR and Slo1 BKCa channels  
*Metallomics* 2017; 9: 634 - 645

**Wang YY., Lin YH., Wu YN., Chen YL., Lin YC., Cheng CY., Chiang HS.**  
Loss of SLC9A3 decreases CFTR protein and causes obstructed azoospermia in mice  
*PLoS Genetics* 2017; 13: 4:e1006715

**Xue XJ., Mutyam V., Thakerar A., Mobley J., Bridges RJ., Rowe SM., Keeling KM., Bedwell DM.**  
Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences  
*Human Molecular Genetics* 2017; 26: 3116 - 3129

**Yan TY., Leng YM., Yang X., Gong YP., Sun HQ., Wang K., Xu WM., Zheng YH., Naren DL., Shi R.**  
High-expressing cystic fibrosis transmembrane conductance regulator interacts with histone deacetylase 2 to promote the development of Ph plus leukemia through the HDAC2-mediated PTEN pathway  
*Leukemia Research* 2017; 57: 9 - 19

**Yang AN., Sun Y., Mao CY., Yang SH., Huang M., Deng M., Ding N., Yang XL., Zhang MH., Jin SJ., Jiang YD., Huang Y.**  
Folate Protects Hepatocytes of Hyperhomocysteinemia Mice From Apoptosis via Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)- Activated Endoplasmic Reticulum Stress  
*Journal of Cellular Biochemistry* 2017; 118: 2921 - 2932

**Zhang JT., Wang Y., Chen JJ., Zhang XH., Da Dong J., Tsang LL., Huang XR., Cai ZM., Lan HY., Jiang XH., Chan HC.**  
Defective CFTR leads to aberrant beta-catenin activation and kidney fibrosis  
*Scientific Reports* 2017; 7: ArNo: 5233

**Zhang Z., Liu FY., Chen J.**  
Conformational Changes of CFTR upon Phosphorylation and ATP Binding  
*Cell* 2017; 170: 483 - +

## Clinical

**Aziz DA., Billoo AG., Qureshi A., Khalid M., Kirmani S.**  
Clinical and laboratory profile of children with Cystic Fibrosis: Experience of a tertiary care center in Pakistan  
*Pakistan Journal of Medical Sciences* 2017; 33: 554 - 559

**Coriati A., Arslanian E., Bouvet GF., Prat A., Seidah NG., Rabasa-Lhoret R., Berthiaume Y.**  
Proprotein Convertase Subtilisin/Kexin type 9 affects insulin but not lipid metabolism in cystic fibrosis  
*Clinical and Investigative Medicine* 2017; 40: E59 - E65

**Leite CDF., Folescu TW., Firmida MD., Cohen RWF., Leao RS., de Freitas FAD., Albano RM., da Costa CH., Marques EA.**  
Monitoring clinical and microbiological evolution of a cystic fibrosis patient over 26 years: experience of a Brazilian CF Centre  
*BMC Pulmonary Medicine* 2017; 17: ArNo: 100

**Mandavdhare HS., Kumar A., Sharma V., Rana SS.**  
Pancreatic lipomatosis in cystic fibrosis: Rare manifestation of an uncommon disease  
*Intractable & Rare Diseases Research* 2017; 6: 150 - 151

**Marson FAL., Bertuzzo CS., Ribeiro JD.**  
Personalized or Precision Medicine? The Example of Cystic Fibrosis  
*Frontiers in Pharmacology* 2017; 8: ArNo: 390

**McColley SA., Schechter MS., Morgan WJ., Pasta DJ., Craib ML., Konstan MW.**  
Risk factors for mortality before age 18 years in cystic fibrosis  
*Pediatric Pulmonology* 2017; 52: 909 - 915

**Ramos KJ., Quon BS., Heltshe SL., Mayer-Hamblett N., Lease ED., Aitken ML., Weiss NS., Goss CH.**  
Heterogeneity in Survival in Adult Patients With Cystic Fibrosis With FEV1 < 30% of Predicted in the United States  
*Chest* 2017; 151: 1320 - 1328

**Ranganathan SC., Hall GL., Sly PD., Stick SM., Douglas TA.**  
Early Lung Disease in Infants and Preschool Children with Cystic Fibrosis What Have We Learned and What Should We Do about It?  
*American Journal of Respiratory and Critical Care Medicine* 2017; 195: 1567 - 1575

**Reznikov LR.**  
Cystic Fibrosis and the Nervous System  
*Chest* 2017; 151: 1147 - 1155

**Ronan NJ., Elborn JS., Plant BJ.**  
Current and emerging comorbidities in cystic fibrosis  
*Presse Medicale* 2017; 46: E125 - E138

**Somayaji R., Ramos KJ., Kapnadak SG., Aitken ML., Goss CH.**  
Common clinical features of CF (respiratory disease and exocrine pancreatic insufficiency)  
*Presse Medicale* 2017; 46: E109 - E124

**Tinsa F., Fredj SH., Hadj IB., Khalsi F., Abdelhak S., Boussetta K., Messaoud T.**  
Pseudo-Bartter syndrome as the sole manifestation of cystic fibrosis in a child with 711+G> T/IVS8-5T mutation: a new face of an old disease  
*Annales de Biologie Clinique* 2017; 75: 466 - 473

**Trandafirescu MF., Moloce A., Ungureanu C., Vasile R., Leon MM., Mastaleru A., Cojocaru E.**  
Insights into clinico-morphological features and management of cystic fibrosis  
*Romanian Journal of Oral Rehabilitation* 2017; 9: 42 - 46

**Vahedi L., Jabarpoor-Bonyadi M., Ghojzadeh M., Vahedi A., Rafeey M.**  
Gender Differences in Clinical Presentations of Cystic Fibrosis Patients in Azeri Turkish Population  
*Tuberculosis and Respiratory Diseases* 2016; 79: 267 - 273

**Walayat S., Hussain N., Patel J., Hussain F., Patel P., Dhillon S., Aulakh B., Chittivelu S.**  
Drug-induced dyspnea versus cystic fibrosis exacerbation: a diagnostic dilemma  
*International Medical Case Reports Journal* 2017; 10: 243 - 246

**Wood J., Mulrennan S., Hill K., Cecins N., Morey S., Jenkins S.**  
Telehealth clinics increase access to care for adults with cystic fibrosis living in rural and remote Western Australia  
*Journal of Telemedicine and Telecare* 2017; 23: 673 - 679

## Diabetes

**Boudreau V., Dubois CL., Desjardins K., Mailhot M., Tremblay F., Rabasa-Lhoret R.**  
Sensitivity and specificity of cystic fibrosis-related diabetes screening methods: which test should be the reference method?  
*Journal of Pediatric Endocrinology & Metabolism* 2017; 30: 885 - 887

**Terliesner N., Vogel M., Steighardt A., Gausche R., Henn C., Hentschel J., Kapellen T., Klamt S., Gebhardt J., Kiess W., Prenzel F.**  
Cystic-fibrosis related-diabetes (CFRD) is preceded by and associated with growth failure and deteriorating lung function  
*Journal of Pediatric Endocrinology & Metabolism* 2017; 30: 815 - 821

Zoni AC., Dominguez-Berjon MF., Esteban-Vasallo MD., Sendra JM., Astray-Mochales J.  
Epidemiology of cystic fibrosis-related diabetes in Madrid (Spain) and frequency of hospitalization  
*European Journal of Internal Medicine* 2017; 42: E14 - E15

## Diagnosis

Athanazio RA., da Silva LVR.F., Vergara AA., Ribeiro AF., Riedi CA., Procianny EDA., Adde FV., Reis FJC., Ribeiro JD., Torres LA., de Fuccio MB., Epifanio M., Firmida MD., Damaceno N., Ludwig-Neto N., Marostice PJC., Rached SZ., et al  
Brazilian guidelines for the diagnosis and treatment of cystic fibrosis  
*Jornal Brasileiro de Pneumologia* 2017; 43: 219 - 245

Choi DH., Li Y., Cutting GR., Searson PC.  
A wearable potentiometric sensor with integrated salt bridge for sweat chloride measurement  
*Sensors and Actuators B-chemical* 2017; 250: 673 - 678

De Boeck K., Vermeulen F., Dupont L.  
The diagnosis of cystic fibrosis  
*Presse Medicale* 2017; 46: E97 - E108

Durc P., Foret F., Pokojova E., Homola L., Skrickova J., Herout V., Dastych M., Vinohradska H., Kuban P.  
New approach for cystic fibrosis diagnosis based on chloride/potassium ratio analyzed in non-invasively obtained skin-wipe sweat samples by capillary electrophoresis with contactless conductometric detection  
*Analytical and Bioanalytical Chemistry* 2017; 409: 3507 - 3514

Faria AG., Marson FAL., Ribeiro AF., Ribeiro JD.  
The correlation between age and sweat chloride levels in sweat tests  
*Revista Portuguesa de Pneumologia* 2017; 23: 227 - 230

Goulet EDB., Asselin A., Gosselin J., Baker LB.  
Measurement of sodium concentration in sweat samples: comparison of 5 analytical techniques  
*Applied Physiology Nutrition and Metabolism* 2017; 42: 861 - 868

Kuehni CE., Schindler M., Mazur A., Malzacher A., Hornung R., Barben J.  
Feasibility and normal values of an integrated conductivity (Nanoduct (TM)) sweat test system in healthy newborns  
*Journal of Cystic Fibrosis* 2017; 16: 465 - 470

Naehrig S., Chao CM., Naehrllich L.  
Cystic Fibrosis Diagnosis and Treatment  
*Deutsches Arzteblatt International* 2017; 114: 564 -

Pedersen KBF.  
Diagnosing cystic fibrosis by elevated sodium concentration in saliva  
*Trace Elements and Electrolytes* 2017; 34: 107 - 110

Zhang CJ., Kim JP., Creer M., Yang J., Liu ZW.  
A smartphone-based chloridometer for point-of-care diagnostics of cystic fibrosis  
*Biosensors & Bioelectronics* 2017; 97: 164 - 168

## Epidemiology

Burgel PR., Bellis G., Elborn JS.  
Modelling future trends in cystic fibrosis demography using the French Cystic Fibrosis Registry: update and sensitivity analysis  
*European Respiratory Journal* 2017; 50: 2:1700763

Frischer T., Eber E., Ellemunter H., Zacharasiewicz A., Kaluza I., Riedler J., Renner S.  
Cystic fibrosis in Austria  
*Wiener Klinische Wochenschrift* 2017; 129: 527 - 532

Isaacs D.  
Survival comparison of patients with cystic fibrosis in Canada and the USA  
*Journal of Paediatrics and Child Health* 2017; 53: 922

Jabarpour-Bonyadi M., Rafeey M., Vahedi A., Vahedi L.  
Genetic pattern of cystic fibrosis patients in Azeri Turkish population  
*Russian Open Medical Journal* 2017; 6: 1:UNSP e0101

Kelly J.  
Environmental scan of cystic fibrosis research worldwide  
*Journal of Cystic Fibrosis* 2017; 16: 367 - 370

Stephenson AL., Stanojevic S., Sykes J., Burgel PR.  
The changing epidemiology and demography of cystic fibrosis  
*Presse Medicale* 2017; 46: E87 - E95

Xu J., Yin Y., Zhang L., Zhang J., Yuan SH., Zhang H.  
Four case reports of Chinese cystic fibrosis patients and literature review  
*Pediatric Pulmonology* 2017; 52: 1020 - 1028

## Exercise

Sani M., Ayubi E.  
Relationship between lung function and Modified Shuttle Test performance in adult patients with cystic fibrosis: a methodological issue  
*Physiotherapy* 2017; 103: 336 - 337

## Gastroenterology

Freedman S., Orenstein D., Black P., Brown P., McCoy K., Stevens J., Grujic D., Clayton R.  
Increased Fat Absorption from Enteral Formula Through an In-line Digestive Cartridge in Patients With Cystic Fibrosis  
*Journal of Pediatric Gastroenterology and Nutrition* 2017; 65: 97 - 101

Garcia JC., Gutierrez IC., Monte BG., Jimenez IR.  
Prenatal diagnosis of fetal bowel obstruction with complicated mi associated with cystic fibrosis  
*Avances en Biomedicina* 2017; 6: 63 - 69

Hohwieler M., Perkhof L., Liebau S., Seufferlein T., Muller M., Illing A., Kleger A.  
Stem cell-derived organoids to model gastrointestinal facets of cystic fibrosis  
*United European Gastroenterology Journal* 2017; 5: 609 - 624

Nikniaz Z., Nikniaz L., Bilan N., Somi MH., Faramarzi E.  
Does probiotic supplementation affect pulmonary exacerbation and intestinal inflammation in cystic fibrosis: a systematic review of randomized clinical trials  
*World Journal of Pediatrics* 2017; 13: 307 - 313

Tabori H., Arnold C., Jaudszus A., Mentzel HJ., Renz DM., Reinsch S., Lorenz M., Michl R., Gerber A., Lehmann T., Mainz JG.  
Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings  
*PLoS One* 2017; 12: 5:e0174463

## Gene Therapy

Guggino WB., Cebotaru L.  
Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments  
*Expert Opinion on Biological Therapy* 2017; 17: 1265 - 1273

Kurosaki F., Uchibori R., Mato N., Sehara Y., Saga Y., Urabe M., Mizukami H., Sugiyama Y., Kume A.  
Optimization of adeno-associated virus vector-mediated gene transfer to the respiratory tract  
*Gene Therapy* 2017; 24: 290 - 297

Naso MF., Tomkowicz B., Perry WL., Strohl WR.  
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy  
*BioDrugs* 2017; 31: 317 - 334

## General Review

**Burgel PR., Fajac I.**

Cystic fibrosis: Current aspects and perspectives  
*Presse Medicale* 2017; 46: E85 - E86

**Klimova B., Kuca K., Novotny M., Maresova P.**

Cystic Fibrosis Revisited - a Review Study  
*Medicinal Chemistry* 2017; 13: 102 - 109

**Savant AP., McColley SA.**

Cystic fibrosis year in review 2016  
*Pediatric Pulmonology* 2017; 52: 1092 - 1102

**Zemanick ET., Daines CL., Dellon EP., Esther CR., Kinghorn B., Ong T., Muhlebach MS.**

Highlights from the 2016 North American Cystic Fibrosis Conference  
*Pediatric Pulmonology* 2017; 52: 1103 - 1110

## Genetics

**De Wachter E., Thomas M., Wanyama SS., Seneca S., Malfroot A.**

What can the CF registry tell us about rare CFTR-mutations? A Belgian study  
*Orphanet Journal of Rare Diseases* 2017; 12: ArNo: 142

**El-Seedy AS., Shafiek H., Kitzis A., Ladeveze V.**

CFTR Gene Mutations in the Egyptian Population : Current and Future Insights for Genetic Screening Strategy  
*Frontiers in Genetics* 2017; 8: ArNo: 37

**Hinzpeter A., Reboul MP., Callebaut I., Zordan C., Costes B., Guichoux J., Iron A., Lacombe D., Martin N., Arveiler B., Fanen P., Fergelot P., Girodon E.**

The importance of functional tests to assess the effect of a new CFTR variant when genotype-phenotype correlation is not possible  
*Clinical Case Reports* 2017; 5: 658 - 663

**Hull BP., Jiramongkolchai P., Turner JH., Olson L., Chandra RK.**

Single nucleotide polymorphisms related to cystic fibrosis in chronic rhinosinusitis-a pilot study  
*International Forum of Allergy & Rhinology* 2017; 7: 467 - 473

**Jiang LY., Jin JM., Wang SS., Zhang FX., Dai YD., Shi LB., Zhang SY.**

CFTR gene mutations and polymorphism are associated with non- obstructive azoospermia: From case-control study  
*Gene* 2017; 626: 282 - 289

**Liu KQ., Liu YP., Li X., Xu KF., Tian XL., Zhang X.**

A novel homozygous complex deletion in CFTR caused cystic fibrosis in a Chinese patient  
*Molecular Genetics and Genomics* 2017; 292: 1083 - 1089

**MacKenzie IER., Paquette V., Gosse F., George S., Chappe F., Chappe V.**

Modeling cystic fibrosis disease progression in patients with the rare CFTR mutation P67L  
*Journal of Cystic Fibrosis* 2017; 16: 335 - 341

**Ozkan-Ariksoysal D.**

Electrochemical Determination of Cystic Fibrosis Gene Mutation by Magnetic Beads-Based Disposable Kit-type Biosensor  
*Journal of the Electrochemical Society* 2017; 164: B258 - B266

**Ribas DIR., Escalante CH., Bortoli CG., de Oliveira CRF., Mikami LR., Riedi CA., Raskin S., Rosario NA., Pereira-Ferrari L. p.Phe508del, p.Gly542X, p.Arg1162X, p.Asn1303Lys, and p.Lys683serfsX38 mutations in CF newborn screening of Brazilian children  
*Clinical Genetics* 2017; 92: 115 - 116**

**Sawicki GS., McKone EF., Millar SJ., Pasta DJ.,**

Konstan MW., Lubarsky B., Wagener JS.  
Patients with Cystic Fibrosis and a G551D or Homozygous F508del Mutation: Similar Lung Function Decline  
*American Journal of Respiratory and Critical Care Medicine* 2017; 195: 1673 - 1676

**Stolzenburg LR., Yang R., Kerschner JL., Fossum S., Xu M., Hoffmann A., Lamar KM., Ghosh S., Wachtel S., Leir SH., Harris A.**

Regulatory dynamics of 11p13 suggest a role for EHF in modifying CF lung disease severity  
*Nucleic Acids Research* 2017; 45: 8773 - 8784

**Szczesniak RD., Li D., Su WJ., Brokamp C., Pestian J., Seid M., Clancy JP.**

Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood  
*American Journal of Respiratory and Critical Care Medicine* 2017; 196: 471 - 478

## Growth & Development

**Chirita-Emandi A., Shepherd S., Kyriakou A., McNeilly JD., Dryden C., Corrigan D., Devenny A., Ahmed SF.**

A retrospective analysis of longitudinal changes in bone mineral content in cystic fibrosis  
*Journal of Pediatric Endocrinology & Metabolism* 2017; 30: 807 - 814

**Doulgeraki A., Petrocheilou A., Petrocheilou G., Chrousos G., Doudounakis SE., Kaditis A.**

Body composition and lung function in children with cystic fibrosis and meconium ileus  
*European Journal of Pediatrics* 2017; 176: 737 - 743

**Gonzalez-Jimenez D., Munoz-Codoceo R., Garriga-Garcia M., Molina-Arias M., Alvarez-Beltran M., Garcia-Romero R., Martinez-Costa C., Meavilla-Olivas SM., Pena-Quintana L., Gallego-Gutierrez S., Marugan-de-Miguelsanz JM., Suarez-Cortina L., et al**

Excess weight in patients with cystic fibrosis: is it always beneficial?  
*Nutricion Hospitalaria* 2017; 34: 578 - 583

**Gupta S., Mukeerjee A., Khadgawat R., Kabra M., Lodha R., Kabra SK.**

Bone Mineral Density of Indian Children and Adolescents with Cystic Fibrosis  
*Indian Pediatrics* 2017; 54: 545 - 549

**Nodoushan AJ., Golzar A., Hassanzad M., Sayedi SJ., Velayati A.**

Low Bone Mineral Density and Associated Factors in Patients with Cystic Fibrosis: A Cross-Sectional Study  
*International Journal of Pediatrics-mashhad* 2017; 5: 5237 - 5244

**Obmann VC., Christe A., Ebner L., Szucs-Farkas Z., Ott SR., Yarram S., Stranzinger E.**

Bone subtraction radiography in adult patients with cystic fibrosis  
*Acta Radiologica* 2017; 58: 929 - 936

**Sharma S., Jaksic M., Fenwick S., Byrnes C., Cundy T.**

Accrual of Bone Mass in Children and Adolescents with Cystic Fibrosis  
*Journal of Clinical Endocrinology & Metabolism* 2017; 102: 1734 - 1739

**Usatin D., Yen EH., McDonald C., Asfour F., Pohl J., Robson J.**

Differences between WHO AND CDC early growth measurements in the assessment of Cystic Fibrosis clinical outcomes  
*Journal of Cystic Fibrosis* 2017; 16: 503 - 509

## Immunology & Inflammation

- Bielen K., Jongers BS., Boddaert J., Raju TK., Lammens C., Malhotra-Kumar S., Jorens PG., Goossens H., Kumar-Singh S.  
Biofilm-Induced Type 2 Innate Immunity in a Cystic Fibrosis Model of *Pseudomonas aeruginosa*  
*Frontiers in Cellular and Infection Microbiology* 2017; 7: ArNo: 274
- Boikos C., Papenburg J., Martineau C., Joseph L., Scheifele D., Chilvers M., Lands LC., De Serres G., Quach C.  
Viral interference and the live-attenuated intranasal influenza vaccine: Results from a pediatric cohort with cystic fibrosis *Human Vaccines & Immunotherapeutics* 2017; 13: 1254 - 1260
- Clazure M., Valdivieso AG., Massip-Copiz MM., Mori C., Dugour AV., Figueroa JM., Santa-Coloma TA.  
Intracellular Chloride Concentration Changes Modulate IL-1 Expression and Secretion in Human Bronchial Epithelial Cultured Cells  
*Journal of Cellular Biochemistry* 2017; 118: 2131 - 2140
- Kormann MSD., Dewerth A., Eichner F., Baskaran P., Hector A., Regamey N., Hartl D., Handgretinger R., Antony JS.  
Transcriptomic profile of cystic fibrosis patients identifies type I interferon response and ribosomal stalk proteins as potential modifiers of disease severity  
*PLoS One* 2017; 12: 8:e0183526
- Kovacic B., Sehl C., Wilker B., Kamler M., Gulbins E., Becker KA.  
Glucosylceramide Critically Contributes to the Host Defense of Cystic Fibrosis Lungs  
*Cellular Physiology and Biochemistry* 2017; 41: 1208 - 1218
- Leveque M., Le Trionnaire S., Del Porto P., Martin-Chouly C.  
The impact of impaired macrophage functions in cystic fibrosis disease progression  
*Journal of Cystic Fibrosis* 2017; 16: 443 - 453
- Marteyn BS., Burgel PR., Meijer L., Witko-Sarsat V.  
Harnessing Neutrophil Survival Mechanisms during Chronic Infection by *Pseudomonas aeruginosa*: Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis  
*Frontiers in Cellular and Infection Microbiology* 2017; 7: ArNo: 243
- Mauch RM., Rossi CL., Aiello TB., Ribeiro JD., Ribeiro AF., Hoiby N., Levy CE.  
Secretory IgA response against *Pseudomonas aeruginosa* in the upper airways and the link with chronic lung infection in cystic fibrosis  
*Pathogens and Disease* 2017; 75: 6:ftx069
- Mesureur J., Feliciano JR., Wagner N., Gomes MC., Zhang LL., Blanco-Gonzalez M., van der Vaart M., O'Callaghan D., Meijer AH., Vergunst AC.  
Macrophages, but not neutrophils, are critical for proliferation of *Burkholderia cenocepacia* and ensuing host-damaging inflammation  
*Plos Pathogens* 2017; 13: 6:e1006437
- Monaghan TM., Negm OH., MacKenzie B., Hamed MR., Shone CC., Humphreys DP., Acharya KR., Wilcox MH.  
High prevalence of subclass-specific binding and neutralizing antibodies against *Clostridium difficile* toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic *C. difficile* infection  
*Clinical and Experimental Gastroenterology* 2017; 10: 169 - 175
- Noel S., Panin N., Beka M., Dhooghe B., Huaux F., Leal T.  
Vardenafil reduces macrophage pro-inflammatory overresponses in cystic fibrosis through PDE5- and CFTR-dependent mechanisms  
*Clinical Science* 2017; 131: 1107 - 1121

Nowak JK., Wojsyk-Banaszak I., Madry E., Wykretowicz A., Krzyzanowska P., Drzymala-Czyz S., Nowicka A., Pogorzelski A., Sapiejka E., Skorupa W., Szczepanik M., Lisowska A., Walkowiak J.  
Increased Soluble VCAM-1 and Normal P-Selectin in Cystic Fibrosis: a Cross-Sectional Study  
*Lung* 2017; 195: 445 - 453

Tarique AA., Sly PD., Holt PG., Boscb A., Ware RS., Logan J., Bell SC., Wainwright CE., Fantino E.  
CFTR-dependent defect in alternatively-activated macrophages in cystic fibrosis  
*Journal of Cystic Fibrosis* 2017; 16: 475 - 482

White MM., Geraghty P., Hayes E., Cox S., Leitch W., Alfawaz B., Lavelle GM., McElvaney OJ., Flannery R., Keenan J., Meleady P., Henry M., Clynes M., Gunaratnam C., McElvaney NG., Reeves EP.  
Neutrophil Membrane Cholesterol Content is a Key Factor in Cystic Fibrosis Lung Disease  
*eBiomedicine* 2017; 23: 173 - 184

## Liver Disease

Klotter V., Gunchick C., Siemers E., Rath T., Hudel H., Naehrlich L., Roderfeld M., Roeb E.  
Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: Results from a prospective longitudinal cohort study  
*PLoS One* 2017; 12: 6:e0178784

Koh C., Sakiani S., Surana P., Zhao XC., Eccleston J., Kleiner DE., Herion D., Liang TJ., Hoofnagle JH., Chernick M., Heller T.  
Adult-Onset Cystic Fibrosis Liver Disease: Diagnosis and Characterization of an Underappreciated Entity  
*Hepatology* 2017; 66: 591 - 601

Krzyzanowska P., Drzymala-Czyz S., Pogorzelski A., Dus-Zuchowska M., Skorupa W., Bober L., Sapiejka E., Oralewska B., Rohovyk N., Moczko J., Nowak J., Wenska-Chyzy E., Rachel M., Lisowska A., Walkowiak J.  
Vitamin K status in cystic fibrosis patients with liver cirrhosis  
*Digestive and Liver Disease* 2017; 49: 672 - 675

Palaniappan SK., Than NN., Thein AW., Moe S., van Mourik I.  
Interventions for preventing and managing advanced liver disease in cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2017; : 8:CD012056

## Meeting Abstracts

Abstracts of the 40th European Cystic Fibrosis Conference Seville, Spain, 7-10 June 2017 Abstracts  
*Journal of Cystic Fibrosis* 2017; 16:

## Microbiology

Agnoli K., Freitag R., Gomes MC., Jenul C., Suppiger A., Mannweiler O., Frauenknecht C., Janser D., Vergunst AC., Eberl L.  
Use of Synthetic Hybrid Strains To Determine the Role of Replicon 3 in Virulence of the *Burkholderia cenocepacia* Complex  
*Applied and Environmental Microbiology* 2017; 83: 13:UNSP e00461

Andersen SB., Ghoul M., Griffin AS., Petersen B., Johansen HK., Molin S.  
Diversity, Prevalence, and Longitudinal Occurrence of Type II Toxin-Antitoxin Systems of *Pseudomonas aeruginosa* Infecting Cystic Fibrosis Lungs  
*Frontiers in Microbiology* 2017; 8: ArNo: 1180

- Ankrum A., Hall BG.  
Population Dynamics of Staphylococcus aureus in Cystic Fibrosis Patients To Determine Transmission Events by Use of Whole-Genome Sequencing  
*Journal of Clinical Microbiology* 2017; 55: 2143 - 2152
- Antonietti V., Boudesocque S., Dupont L., Farvacques N., Cezard C., Da Nascimento S., Raimbert JF., Socrier L., Robin TJ., Morandat S., El Kirat K., Mullie C., Sonnet P.  
Synthesis, iron(III) complexation properties, molecular dynamics simulations and P. aeruginosa siderophore-like activity of two pyoverdine analogs  
*European Journal of Medicinal Chemistry* 2017; 137: 338 - 350
- Bacci G., Mengoni A., Fiscarelli E., Segata N., Taccetti G., Dolce D., Paganin P., Morelli P., Tuccio V., De Alessandri A., Lucidi V., Bevivino A.  
A Different Microbiome Gene Repertoire in the Airways of Cystic Fibrosis Patients with Severe Lung Disease  
*International Journal of Molecular Sciences* 2017; 18: 8:1654
- Bach E., Sant'Anna FH., dos Passos JFM., Balsanelli E., de Baura VA., Pedrosa FD., de Souza EM., Passaglia LMP.  
Detection of misidentifications of species from the Burkholderia cepacia complex and description of a new member, the soil bacterium Burkholderia catarinensis sp nov.  
*Pathogens and Disease* 2017; 75: 6:ftx076
- Balloy V., Koshy R., Perra L., Corvol H., Chignard M., Guillot L., Scaria V.  
Bronchial Epithelial Cells from Cystic Fibrosis Patients Express a Specific Long Non-coding RNA Signature upon Pseudomonas aeruginosa Infection  
*Frontiers in Cellular and Infection Microbiology* 2017; 7: ArNo: 218
- Barbosa C., Trebosc V., Kemmer C., Rosenstiel P., Beardmore R., Schulenburg H., Jansen G.  
Alternative Evolutionary Paths to Bacterial Antibiotic Resistance Cause Distinct Collateral Effects  
*Molecular Biology and Evolution* 2017; 34: 2229 - 2244
- Bedi B., Maurice NM., Ciavatta VT., Lynn KS., Yuan ZH., Molina SA., Joo M., Tyor WR., Goldberg JB., Koval M., Hart CM., Sadikot RT.  
Peroxisome proliferator-activated receptor-gamma agonists attenuate biofilm formation by Pseudomonas aeruginosa  
*FASEB Journal* 2017; 31: 3608 - 3621
- Bensman TJ., Jayne JG., Sun ML., Kimura E., Meinert J., Wang JC., Schaal JB., Tran D., Rao AP., Akbari O., Selsted ME., Beringer PM.  
Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation  
*Antimicrobial Agents and Chemotherapy* 2017; 61: 8:e00154-17
- Bernier SP., Hum C., Li X., O'Toole GA., Magarvey NA., Surette MG.  
Pseudomonas aeruginosa-Derived Rhamnolipids and Other Detergents Modulate Colony Morphotype and Motility in the Burkholderia cepacia Complex  
*Journal of Bacteriology* 2017; 199: 13:UNSP e00171
- Billard L., Le Berre R., Pilorge L., Payan C., Hery-Arnaud G., Vallet S.  
Viruses in cystic fibrosis patients' airways  
*Critical Reviews in Microbiology* 2017; 43: 690 - 708
- Blanchard AC., Horton E., Stanojevic S., Taylor L., Waters V., Ratjen F.  
Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis  
*Journal of Cystic Fibrosis* 2017; 16: 395 - 400
- Bosch L., Bosch B., De Boeck K., Nawrot T., Meyts I., Vanneste D., Le Bourlegat CA., Croda J., da Silva LVRF.  
Cystic fibrosis carriership and tuberculosis: hints toward an evolutionary selective advantage based on data from the Brazilian territory  
*BMC Infectious Diseases* 2017; 17: ArNo: 340
- Briard B., Rasoldier V., Bomme P., ElAouad N., Guerreiro C., Chassagne P., Muszkieta L., Latge JP., Mulard L., Beauvais A.  
Dirhamnolipids secreted from Pseudomonas aeruginosa modify antifungal susceptibility of Aspergillus fumigatus by inhibiting beta 1,3 glucan synthase activity  
*ISME Journal* 2017; 11: 1578 - 1591
- Chibabhai V., Lowman W.  
Epidemiology of cystic fibrosis respiratory pathogens isolated at a South African Hospital, 2006-2010  
*Southern African Journal of Infectious Diseases* 2016; 31: 106 - 111
- Darch SE., Ibberson CB., Whiteley M.  
Evolution of Bacterial "Frenemies"  
*mBio* 2017; 8: 3:e00675-17
- Davies CB., Harrison MD., Huygens F.  
Pseudomonas aeruginosa Trent and zinc homeostasis  
*FEMS Microbiology Letters* 2017; 364: 16:fnx151
- Dubois CL., Boudreau V., Tremblay F., Lavoie A., Berthiaume Y., Rabasa-Lhoret R., Coriati A.  
Association between glucose intolerance and bacterial colonisation in an adult population with cystic fibrosis, emergence of Stenotrophomonas maltophilia  
*Journal of Cystic Fibrosis* 2017; 16: 418 - 424
- Edwards BD., Greysson-Wong J., Somayaji R., Waddell B., Whelan FJ., Storey DG., Rabin HR., Surette MG., Parkins MD.  
Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study  
*Journal of Clinical Microbiology* 2017; 55: 2074 - 2085
- Esposito A., Pompilio A., Bettua C., Crocetta V., Giacobazzi E., Fiscarelli E., Jousson O., Di Bonaventura G.  
Evolution of Stenotrophomonas maltophilia in Cystic Fibrosis Lung over Chronic Infection: A Genomic and Phenotypic Population Study  
*Frontiers in Microbiology* 2017; 8: ArNo: 1590
- Fazli M., Rybtke M., Steiner E., Weidel E., Berthelsen J., Groizeleau J., Bin W., Zhi BZ., Zhang YM., Kaever V., Givskov M., Hartmann RW., Eberl L., Tolker-Nielsen T.  
Regulation of Burkholderia cenocepacia biofilm formation by RpoN and the c-di-GMP effector BerB  
*Microbiologyopen* 2017; 6: 4:e480
- Filipic B., Malesevic M., Vasiljevic Z., Lukic J., Novovic K., Kojic M., Jovcic B.  
Uncovering Differences in Virulence Markers Associated with Achromobacter Species of CF and Non-CF Origin  
*Frontiers in Cellular and Infection Microbiology* 2017; 7: ArNo: 224
- Fischer S., Greipel L., Klockgether J., Dorda M., Wiehlmann L., Cramer N., Tummeler B.  
Multilocus amplicon sequencing of Pseudomonas aeruginosa cystic fibrosis airways isolates collected prior to and after early antipseudomonal chemotherapy  
*Journal of Cystic Fibrosis* 2017; 16: 346 - 352
- Fouhy F., Ronan NJ., O'Sullivan O., McCarthy Y., Walsh AM., Murphy DM., Daly M., Flanagan ET., Fleming C., McCarthy M., Shortt C., Eustace JA., Shanahan F., Rea MC., Ross RP., Stanton C., Plant BJ.  
A pilot study demonstrating the altered gut microbiota functionality in stable adults with Cystic Fibrosis  
*Scientific Reports* 2017; 7: ArNo: 6685

- Gade SS., Norskov-Lauritsen N., Ridderberg W. Prevalence and species distribution of *Achromobacter* sp cultured from cystic fibrosis patients attending the Aarhus centre in Denmark  
*Journal of Medical Microbiology* 2017; 66: 686 - 689
- Gholami S., Tabatabaei M., Sohrabi N. Comparison of biofilm formation and antibiotic resistance pattern of *Pseudomonas aeruginosa* in human and environmental isolates  
*Microbial Pathogenesis* 2017; 109: 94 - 98
- Gilpin DF., Nixon KA., Bull M., McGrath SJ., Sherrard L., Rolain JM., Mahenthiralingam E., Elborn JS., Tunney MM. Evidence of persistence of *Prevotella* spp. in the cystic fibrosis lung  
*Journal of Medical Microbiology* 2017; 66: 825 - 832
- Grosse-Onnebrink J., Stehling F., Tschiedel E., Olivier M., Mellies U., Schmidt R., Buer J., Rath PM., Steinmann J. Bacteraemia and fungaemia in cystic fibrosis patients with febrile pulmonary exacerbation: a prospective observational study  
*BMC Pulmonary Medicine* 2017; 17: ArNo: 96
- Hassan AA., Maldonado RF., dos Santos SC., Di Lorenzo F., Silipo A., Coutinho CP., Cooper VS., Molinaro A., Valvano MA., Sa-Correia I. Structure of O-Antigen and Hybrid Biosynthetic Locus in *Burkholderia cenocepacia* Clonal Variants Recovered from a Cystic Fibrosis Patient  
*Frontiers in Microbiology* 2017; 8: ArNo: 1027
- Hewer SCL., Smyth AR. Antibiotic strategies for eradicating *Pseudomonas aeruginosa* in people with cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2017; : 4:CD004197
- Hill PJ., Scordo JM., Arcos J., Kirkby SE., Wewers MD., Wozniak DJ., Torrelles JB. Modifications of *Pseudomonas aeruginosa* cell envelope in the cystic fibrosis airway alters interactions with immune cells  
*Scientific Reports* 2017; 7: ArNo: 4761
- Hutchins CF., Moore G., Thompson KA., Webb J., Walker JT. Contamination of hospital tap water: the survival and persistence of *Pseudomonas aeruginosa* on conventional and 'antimicrobial' outlet fittings  
*Journal of Hospital Infection* 2017; 97: 156 - 161
- Jones CJ., Wozniak DJ. Psl Produced by Mucoid *Pseudomonas aeruginosa* Contributes to the Establishment of Biofilms and Immune Evasion  
*mBio* 2017; 8: 3:e00864-17
- Kaditis AG., Miligkos M., Bossi A., Colombo C., Hatziaiorou E., Kashirskaya N., de Monestrol I., Thomas M., Mei-Zahav M., Chrousos G., Zolin A. Effect of allergic bronchopulmonary aspergillosis on FEV1 in children and adolescents with cystic fibrosis: a European Cystic Fibrosis Society Patient Registry analysis  
*Archives of Disease in Childhood* 2017; 102: 742 - 747
- Kang D., Kirienko NV. High-Throughput Genetic Screen Reveals that Early Attachment and Biofilm Formation Are Necessary for Full Pyoverdine Production by *Pseudomonas aeruginosa*  
*Frontiers in Microbiology* 2017; 8: ArNo: 1707
- Kenna DTD., Lilley D., Coward A., Martin K., Perry C., Pike R., Hill R., Turton JF. Prevalence of *Burkholderia* species, including members of *Burkholderia cepacia* complex, among UK cystic and non-cystic fibrosis patients  
*Journal of Medical Microbiology* 2017; 66: 490 - 501
- Kishta OA., Guo Y., Mofarrahi M., Stana F., Lands LC., Hussain SNA. Pulmonary *Pseudomonas aeruginosa* infection induces autophagy and proteasome proteolytic pathways in skeletal muscles: effects of a pressurized whey protein-based diet in mice  
*Food & Nutrition Research* 2017; 61: ArNo: 1325309
- Lee K., Yoon SS. *Pseudomonas aeruginosa* Biofilm, a Programmed Bacterial Life for Fitness  
*Journal of Microbiology and Biotechnology* 2017; 27: 1053 - 1064
- Linnane B., Collins L., Bussmann N., O'Connell NH., Dunne CP. Medical devices for cystic fibrosis care may be portable reservoirs of potential pathogens  
*Journal of Hospital Infection* 2017; 96: 397 - 398
- Lopez-Causape C., Sommer LM., Cabot G., Rubio R., Ocampo-Sosa AA., Johansen HK., Figuerola J., Canton R., Kidd TJ., Molin S., Oliver A. Evolution of the *Pseudomonas aeruginosa* mutational resistome in an international Cystic Fibrosis clone  
*Scientific Reports* 2017; 7: ArNo: 5555
- Malesevic M., Vasiljevic Z., Sobic A., Filipic B., Novovic K., Kojic M., Jovcic B. Virulence traits associated with *Burkholderia cenocepacia* ST856 epidemic strain isolated from cystic fibrosis patients  
*Antimicrobial Resistance and Infection Control* 2017; 6: ArNo: 57
- Maunder E., Welch M. Matrix exopolysaccharides; the sticky side of biofilm formation  
*FEMS Microbiology Letters* 2017; 364: 13:fnx120
- McCarthy RR., Mazon-Moya MJ., Moscolo JA., Hao YA., Lam JS., Bordi C., Mostowy S., Filloux A. Cyclic-di-GMP regulates lipopolysaccharide modification and contributes to *Pseudomonas aeruginosa* immune evasion  
*Nature Microbiology* 2017; 2: 6:17027
- Metz J., Eber E., Resch B. Respiratory Syncytial Virus Infection-associated Hospitalization Rates in Infants and Children with Cystic Fibrosis  
*Pediatric Infectious Disease Journal* 2017; 36: 545 - 548
- Michl RK., Beck JF., Mainz JG. Cystic Fibrosis Patient's best friend? Potential Transmission of *Pseudomonas aeruginosa* from a Dog  
*Klinische Padiatrie* 2017; 229: 245 - 246
- Moller ME., Alanin MC., Gronhoj C., Aanaes K., Hoiby N., von Buchwald C. Sinus bacteriology in patients with cystic fibrosis or primary ciliary dyskinesia: A systematic review  
*American Journal of Rhinology & Allergy* 2017; 31: 293 - 298
- Montesinos I., Argudin MA., Hites M., Ahajjam F., Dodemont M., Dayaran C., Bakkali M., Etienne I., Jacobs F., Knoop C., Patteet S., Lagrou K. Culture-Based Methods and Molecular Tools for Azole-Resistant *Aspergillus fumigatus* Detection in a Belgian University Hospital  
*Journal of Clinical Microbiology* 2017; 55: 2391 - 2399
- Narayanamurthy V., Sweetnam JM., Denner DR., Chen LW., Naureckas ET., Laxman B., White SR. The metabolic footprint of the airway bacterial community in cystic fibrosis  
*Microbiome* 2017; 5: ArNo: 67
- Nishiuchi Y., Iwamoto T., Maruyama F. Infection Sources of a Common Non-tuberculous Mycobacterial Pathogen, *Mycobacterium avium* Complex  
*Frontiers in Medicine* 2017; 4: ArNo: 27
- Noni M., Katelari A., Kapi A., Stathi A., Dimopoulos G., Doudounakis SE. *Scedosporium apiospermum* complex in cystic fibrosis; should we treat?  
*Mycoses* 2017; 60: 594 - 599

- Noto MJ., Burns WJ., Beavers WN., Skaar EP.**  
Mechanisms of Pyocyanin Toxicity and Genetic Determinants of Resistance in *Staphylococcus aureus*  
*Journal of Bacteriology* 2017; 199: 17:UNSP e00221
- O'Brien S., Fothergill JL.**  
The role of multispecies social interactions in shaping *Pseudomonas aeruginosa* pathogenicity in the cystic fibrosis lung  
*FEMS Microbiology Letters* 2017; 364: 15:fnx128
- Oh J., Li XH., Kim SK., Lee JH.**  
Post-secretional activation of Protease IV by quorum sensing in *Pseudomonas aeruginosa*  
*Scientific Reports* 2017; 7: ArNo: 4416
- Orazi G., O'Toole GA.**  
*Pseudomonas aeruginosa* Alters *Staphylococcus aureus* Sensitivity to Vancomycin in a Biofilm Model of Cystic Fibrosis Infection  
*mBio* 2017; 8: 4:e00873-17
- Pires DP., Dotsch A., Anderson EM., Hao YA., Khursigara CM., Lam JS., Sillankorva S., Azeredo J.**  
A Genotypic Analysis of Five *P. aeruginosa* Strains after Biofilm Infection by Phages Targeting Different Cell Surface Receptors  
*Frontiers in Microbiology* 2017; 8: ArNo: 1229
- Poonja A., Heirali A., Workentine M., Storey DG., Somayaji R., Rabin HR., Surette MG., Parkins MD.**  
Effect of freezing sputum on *Pseudomonas aeruginosa* population heterogeneity  
*Journal of Cystic Fibrosis* 2017; 16: 353 - 357
- Prior AR., Gunaratnam C., Humphreys H.**  
*Ralstonia* species - do these bacteria matter in cystic fibrosis?  
*Paediatric Respiratory Reviews* 2017; 23: 78 - 83
- Psoter KJ., De Roos AJ., Wakefield J., Mayer JD., Rosenfeld M.**  
Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis  
*BMC Infectious Diseases* 2017; 17: ArNo: 411
- Rautemaa V., Green HD., Jones AM., Rautemaa-Richardson R.**  
High level of beta-(1,3)-D-glucan antigenaemia in cystic fibrosis in the absence of invasive fungal disease  
*Diagnostic Microbiology and Infectious Disease* 2017; 88: 316 - 321
- Reddy A., Greenberger PA.**  
Allergic Bronchopulmonary Aspergillosis  
*Journal of Allergy and Clinical Immunology-in Practice* 2017; 5: 866 - 867
- Reece E., Segurado R., Jackson A., McClean S., Renwick J., Grealley P.**  
Co-colonisation with *Aspergillus fumigatus* and *Pseudomonas aeruginosa* is associated with poorer health in cystic fibrosis patients: an Irish registry analysis  
*BMC Pulmonary Medicine* 2017; 17: ArNo: 70
- Rieger M., Mauch H., Hakenbeck R.**  
Long Persistence of a *Streptococcus pneumoniae* 23F Clone in a Cystic Fibrosis Patient  
*mSphere* 2017; 2: 3:e00201-17
- Roux D., Weatherholt M., Clark B., Gadjeva M., Renaud D., Scott D., Skurnik D., Priebe GP., Pier G., Gerard C., Yoder-Himes DR.**  
Immune Recognition of the Epidemic Cystic Fibrosis Pathogen *Burkholderia dolosa*  
*Infection and Immunity* 2017; 85: 6:e00765
- Sabino R., Carolino E., Moss RB., Banaei N., Verissimo C., Stevens DA.**  
Susceptibility of *Candida albicans* from Cystic Fibrosis Patients  
*Mycopathologia* 2017; 182: 863 - 867
- Scoffone VC., Chiarelli LR., Trespidi G., Mentasti M., Riccardi G., Buroni S.**  
*Burkholderia cenocepacia* Infections in Cystic Fibrosis Patients: Drug Resistance and Therapeutic Approaches  
*Frontiers in Microbiology* 2017; 8: ArNo: 1592
- Sherrard LJ., Tay GT., Butler CA., Wood ME., Yerkovich S., Ramsay KA., Reid DW., Moore VL., Kidd TJ., Bell SC.**  
Tropical Australia is a potential reservoir of non-tuberculous mycobacteria in cystic fibrosis  
*European Respiratory Journal* 2017; 49: 5:1700046
- Smith WD., Bardin E., Cameron L., Edmondson CL., Farrant KV., Martin I., Murphy RA., Soren O., Turnbull AR., Wierre-Gore N., Alton EW., Bundy JG., Bush A., Connett GJ., Faust SN., Filloux A., Freemont PS., Jones AL., Takats Z., Web**  
Current and future therapies for *Pseudomonas aeruginosa* infection in patients with cystic fibrosis  
*FEMS Microbiology Letters* 2017; 364: 14:fnx121
- Sobin L., Kawai K., Irace AL., Gergin O., Cunningham M., Sawicki GS., Adil EA.**  
Microbiology of the Upper and Lower Airways in Pediatric Cystic Fibrosis Patients  
*Otolaryngology-Head and Neck Surgery* 2017; 157: 302 - 308
- Stelzer-Braid S., Liu N., Doumit M., D'Cunha R., Belessis Y., Jaffe A., Rawlinson WD.**  
Association of rhinovirus with exacerbations in young children affected by cystic fibrosis: Preliminary data  
*Journal of Medical Virology* 2017; 89: 1494 - 1497
- To KKW., Yip CCY., Yuen KY.**  
Rhinovirus - From bench to bedside  
*Journal of the Formosan Medical Association* 2017; 116: 496 - 504
- Tognon M., Kohler T., Gdaniec BG., Hao YA., Lam JS., Beaume M., Luscher A., Buckling A., van Delden C.**  
Co-evolution with *Staphylococcus aureus* leads to lipopolysaccharide alterations in *Pseudomonas aeruginosa*  
*ISME Journal* 2017; 11: 2233 - 2243
- Williamson KM., Wagner BD., Robertson CE., Johnson EJ., Zemanick ET., Harris JK.**  
Impact of enzymatic digestion on bacterial community composition in CF airway samples  
*PEERJ* 2017; 5: ArNo: e3362
- Yang JY., Toyofuku M., Sakai R., Nomura N.**  
Influence of the alginate production on cell-to-cell communication in *Pseudomonas aeruginosa* PAO1  
*Environmental Microbiology Reports* 2017; 9: 239 - 249
- Zautner AE., Gross U., Emele MF., Hagen RM., Frickmann H.**  
More Pathogenicity or Just More Pathogens?-On the Interpretation Problem of Multiple Pathogen Detections with Diagnostic Multiplex Assays  
*Frontiers in Microbiology* 2017; 8: ArNo: 1210

## Nutrition

- Calvo-Leima J., Hulst JM., Asseiceira I., Claes I., Garriga M., Colombo C., Fornes V., Woodcock S., Martins T., Boon M., Ruperto M., Walet S., Speziali C., Witters P., Masip E., Barreto C., de Boeck K., Ribes-Koninckx C.**  
Nutritional status, nutrient intake and use of enzyme supplements in paediatric patients with Cystic Fibrosis; a European multicentre study with reference to current guidelines  
*Journal of Cystic Fibrosis* 2017; 16: 510 - 518
- Filigno SS., Robson SM., Szczesniak RD., Chamberlin LA., Baker MA., Sullivan SM., Kroner J., Powers SW.**  
Macronutrient intake in preschoolers with cystic fibrosis and the relationship between macronutrients and growth  
*Journal of Cystic Fibrosis* 2017; 16: 519 - 524
- Hloch O., Charvat J., Fila L., Jan H.**  
Immunonutrition in patients with cystic fibrosis leads to drop of serum amyloid A and increase of oxidative stress  
*Journal of Clinical Biochemistry and Nutrition* 2017; 60: 176 - 179

**Jagannath VA., Thaker V., Chang AB., Price AI.**  
Vitamin K supplementation for cystic fibrosis (Review)  
*Cochrane Database of Systematic Reviews 2017*; :  
8:CD008482

**Li L., Krause L., Somerset S.**  
Associations between micronutrient intakes and gut microbiota in a group of adults with cystic fibrosis  
*Clinical Nutrition 2017*; 36: 1097 - 1104

**Mandal A., Priyadarshi M., Jat K., Kabra SK.**  
Infantile Tremor Syndrome and Subdural Hemorrhage in an Infant with Cystic Fibrosis  
*Journal of Tropical Pediatrics 2017*; 63: 328 - 332

**Murphy AJ., Hill RJ., Buntain H., White M., Brookes D., Davies PSW.**  
Nutritional status of children with clinical conditions  
*Clinical Nutrition 2017*; 36: 788 - 792

**Okebukola PO., Kansra S., Barrett J.**  
Vitamin E supplementation in people with cystic fibrosis (Review)  
*Cochrane Database of Systematic Reviews 2017*; :  
3:CD009422

**Pincikova T., Paquin-Proulx D., Sandberg JK., Flodstrom-Tullberg M., Hjelte L.**  
Vitamin D treatment modulates immune activation in cystic fibrosis  
*Clinical and Experimental Immunology 2017*; 189: 359 - 371

**Smyth RL., Rayner O.**  
Oral calorie supplements for cystic fibrosis  
*Cochrane Database of Systematic Reviews 2017*; :  
5:CD000406

**Woestenenk JW., Schulkes DA., Schipper HS., van der Ent CK., Houwen RHJ.**  
Dietary intake and lipid profile in children and adolescents with cystic fibrosis  
*Journal of Cystic Fibrosis 2017*; 16: 410 - 417

## Physiotherapy

**Brown SD., White R., Tobin P.**  
Keep them breathing: Cystic fibrosis pathophysiology, diagnosis, and treatment  
*JAAPA- Journal of the American Academy of Physician Assistants 2017*; 30: 23 - 27

**Gorman J., Sparrow E., Krautbauer K.**  
Fluid mechanics and sound generation for lung-clearance therapy Advanced design modality for a biomedical therapeutic device  
*International Journal of Numerical Methods for Heat & Fluid Flow 2017*; 27: 820 - 838

**Hortal MCR., Nygren-Bonnier M., Hjelte L.**  
Non-invasive Ventilation as Airway Clearance Technique in Cystic Fibrosis  
*Physiotherapy Research International 2017*; 22:  
3:e1667

**Konstan MW., Wagener JS., VanDevanter DR., Pasta DJ., Millar SJ., Morgan WJ.**  
Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention  
*Pediatric Pulmonology 2017*; 52: 1013 - 1019

**Morrison L., Innes S.**  
Oscillating devices for airway clearance in people with cystic fibrosis  
*Cochrane Database of Systematic Reviews 2017*; :  
5:CD006842

## Psychosocial

**Aguiar KCA., Marson FAL., Gomez CCS., Pereira MC., Paschoal IA., Ribeiro AF., Ribeiro JD.**  
Physical performance, quality of life and sexual satisfaction evaluation in adults with cystic fibrosis: An unexplored correlation  
*Revista Portuguesa de Pneumologia 2017*; 23: 179 - 192

**Bosch B., Bilton D., Sosnay P., Raraigh KS., Mak DYF., Ishiguro H., Gulmans V., Thomas M., Cuppens H., Amaral M., De Boeck K.**  
Ethnicity impacts the cystic fibrosis diagnosis: A note of caution  
*Journal of Cystic Fibrosis 2017*; 16: 488 - 491

**Broekema K., Weber KM.**  
Disclosures of Cystic Fibrosis-Related Information to Romantic Partners  
*Qualitative Health Research 2017*; 27: 1575 - 1585

**Christofides E., Stroud K., Tullis DE., O'Doherty K.**  
The Meanings of Helping: An Analysis of Cystic Fibrosis Patients' Reasons for Participating in Biomedical Research  
*Journal of Empirical Research on Human Research Ethics 2017*; 12: 180 - 190

**Hayeems RZ., Miller FA., Barg CJ., Bombard Y., Carroll JC., Tam K., Kerr E., Chakraborty P., Potter BK., Patton S., Bytautas JP., Taylor L., Davies C., Milburn J., Price A., Gonska T., Keenan K., Ratjen F., Guttman A.**  
Psychosocial Response to Uncertain Newborn Screening Results for Cystic Fibrosis  
*Journal of Pediatrics 2017*; 184: 165 - +

**Mikesell CL., Kempainen RR., Laguna TA., Menk JS., Wey AR., Gaillard PR., Regelman WE.**  
Objective Measurement of Adherence to Out-Patient Airway Clearance Therapy by High-Frequency Chest Wall Compression in Cystic Fibrosis  
*Respiratory Care 2017*; 62: 920 - 927

**Moola FJ., Henry LAV., Huynh E., Stacey JA., Faulkner GEJ.**  
They know it's safe - they know what to expect from that face: perceptions towards a cognitive-behavioural counselling programme among caregivers of children with cystic fibrosis  
*Journal of Clinical Nursing 2017*; 26: 2932 - 2943

**Morton RW., Elphick HE., Edwards E., Daw WJ., West NS.**  
Investigating the feasibility of text message reminders to improve adherence to nebulized medication in children and adolescents with cystic fibrosis  
*Patient Preference and Adherence 2017*; 11: 861 - 869

**Price DM., Knotts SE.**  
Communication, Comfort, and Closure for the Patient With Cystic Fibrosis at the End of Life: The Role of the Bedside Nurse  
*Journal of Hospice & Palliative Nursing 2017*; 19: 298 - 302

**Smyth W., Abernethy G., Jessup M., Douglas T., Shields L.**  
Family-centred care in cystic fibrosis: a pilot study in North Queensland, Australia  
*Nursing Open 2017*; 4: 168 - 173

**Tappenden P., Sadler S., Wildman M.**  
An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis  
*Pharmacoeconomics 2017*; 35: 647 - 659

**van Horck M., Winkens B., Wesseling G., de Winter-de Groot K., de Vreede I., Jobsis Q., Dompeling E.**  
Factors associated with changes in health-related quality of life in children with cystic fibrosis during 1-year follow-up  
*European Journal of Pediatrics 2017*; 176: 1047 - 1054

**Ward N., Stiller K., Rowe H., Holland AE.**  
The psychometric properties of the Leicester Cough Questionnaire and Respiratory Symptoms in CF tool in cystic fibrosis: A preliminary study  
*Journal of Cystic Fibrosis 2017*; 16: 425 - 432

**Zobell JT., Schwab E., Collingridge DS., Ball C., Nohavec R., Asfour F.**  
Impact of pharmacy services on cystic fibrosis medication adherence  
*Pediatric Pulmonology 2017*; 52: 1006 - 1012

## Pulmonology

**Belanger AR., Nguyen K., Osman U., Gilbert CR., Allen K., Al Rais AF., Yarmus L., Akulian JA.**  
Pleural effusions in non-transplanted cystic fibrosis patients

*Journal of Cystic Fibrosis* 2017; 16: 499 - 502

**Caretti A., Vasso M., Bonezzi FT., Gallina A., Trincherà M., Rossi A., Adami R., Casas J., Falleni M., Tosi D., Bragonzi A., Ghidoni R., Gelfi C., Signorelli P.**

Myriocin treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids  
*Naunyn-schmiedeberg's Archives of Pharmacology* 2017; 390: 775 - 790

**Cook DP., Adam RJ., Zarei K., Deonovic B., Stroik MR., Gansemer ND., Meyerholz DK., Au KF., Stoltz DA.**

CF airway smooth muscle transcriptome reveals a role for PYK2

*JCI Insight* 2017; 2: 17:e95332

**Flight WG., Barry PJ., Bright-Thomas RJ., Butterfield S., Ashleigh R., Jones AM.**

Outcomes Following Bronchial Artery Embolisation for Haemoptysis in Cystic Fibrosis  
*Cardiovascular and Interventional Radiology* 2017; 40: 1164 - 1168

**Grassme H., Henry B., Ziobro R., Becker KA., Riethmüller J., Gardner A., Seitz AP., Steinmann J., Lang S., Ward C., Schuchman EH., Caldwell CC., Kamler M., Edwards MJ., Brodli M., Gulbins E.**  
beta 1-Integrin Accumulates in Cystic Fibrosis Luminal Airway Epithelial Membranes and Decreases Sphingosine, Promoting Bacterial Infections

*Cell Host & Microbe* 2017; 21: 707 -

**Halderman AA., West N., Benke J., Roxbury CR., Lin SY.**

F508del genotype in endoscopic sinus surgery: do differences in outcomes exist between genotypic subgroups?

*International Forum of Allergy & Rhinology* 2017; 7: 459 - 466

**Moran F., Bradley JM., Piper AJ.**

Non-invasive ventilation for cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2017; : 2:CD002769

**Ocellli A., Soize S., Ranc C., Giovannini-Chami L., Bailly C., Leloutre B., Boyer C., Baque-Juston M.**

Bronchocele density in cystic fibrosis as an indicator of allergic bronchopulmonary aspergillosis: A preliminary study  
*European Journal of Radiology* 2017; 93: 195 - 199

**Paul L.**

Is bronchoscopy an obsolete tool in cystic fibrosis? The role of bronchoscopy in cystic fibrosis and its clinical use  
*Journal of Thoracic Disease* 2017; 9:

**Pittman JE., Noah H., Calloway HE., Davis SD., Leigh MW., Drumm M., Sagei SD., Accurso FJ., Knowles MR., Sontag MK.**  
Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early *Pseudomonas aeruginosa* infection  
*PLoS One* 2017; 12: 5:e0177215

**Sandefur Cl., Boucher RC., Elston TC.**

Mathematical model reveals role of nucleotide signaling in airway surface liquid homeostasis and its dysregulation in cystic fibrosis  
*Proceedings of the National Academy of Sciences of the United States of America* 2017; 114: E7272 - E7281

**Scott LK., Toner R.**

Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations  
*Lung* 2017; 195: 397 - 401

**Somayaji R., Goss CH., Khan U., Neradilek M., Neuzil KM., Ortiz JR.**

Cystic Fibrosis Pulmonary Exacerbations Attributable to Respiratory Syncytial Virus and Influenza: A Population-Based Study  
*Clinical Infectious Diseases* 2017; 64: 1760 - 1767

**Sun A., Phelps T., Yao CY., Venkatesh AG., Conrad D., Hall DA.**

Smartphone-Based pH Sensor for Home Monitoring of Pulmonary Exacerbations in Cystic Fibrosis  
*Sensors* 2017; 17: 6:1245

**Szczesniak R., Heltshe SL., Stanojevic S., Mayer-Hamblett N.**

Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher

*Journal of Cystic Fibrosis* 2017; 16: 318 - 326

**Tumin D., Hayes D., Kirkby SE., Tobias JD., McKee C.**

Safety of endoscopic sinus surgery in children with cystic fibrosis

*International Journal of Pediatric Otorhinolaryngology* 2017; 98: 25 - 28

**Zang XL., Perez JJ., Jones CM., Monge ME., McCarty NA., Stecenko AA., Fernandez FM.**

Comparison of Ambient and Atmospheric Pressure Ion Sources for Cystic Fibrosis Exhaled Breath Condensate Ion Mobility-Mass Spectrometry Metabolomics  
*Journal of the American Society for Mass Spectrometry* 2017; 28: 1489 - 1496

## Radiology

**Averill S., Lubner MG., Menias CO., Bhalla S., Mellnick VM., Kennedy TA., Pickhardt PJ.**

Multisystem Imaging Findings of Cystic Fibrosis in Adults: Recognizing Typical and Atypical Patterns of Disease  
*American Journal of Roentgenology* 2017; 209: 3 - 18

**Caudri D., Zitter D., Bronsveld I., Tiddens H.**

Is sweat chloride predictive of severity of cystic fibrosis lung disease assessed by chest computed tomography?  
*Pediatric Pulmonology* 2017; 52: 1135 - 1141

**Kahn J., Kaul D., Grupp U., Boning G., Renz D., Staab D., Schreiter V., Streitparth F.**

Computed Tomography in Cystic Fibrosis: Combining Low-Dose Techniques and Iterative Reconstruction  
*Journal of Computer Assisted Tomography* 2017; 41: 668 - 674

**Kolodziej M., de Veer MJ., Cholewa M., Egan GF., Thompson BR.**

Lung function imaging methods in Cystic Fibrosis pulmonary disease  
*Respiratory Research* 2017; 18: ArNo: 96

**Krueger-Ziolek S., Schullcke B., Gong B., Muller-Lisse U., Moeller K.**

EIT based pulsatile impedance monitoring during spontaneous breathing in cystic fibrosis  
*Physiological Measurement* 2017; 38: 1214 - 1225

**Marshall H., Horsley A., Taylor CJ., Smith L., Hughes D., Horn FC., Swift AJ., Parra-Robles J., Hughes PJ., Norquay G., Stewart NJ., Collier GJ., Teare D., Cunningham S., Aldag I., Wild JM.**

Detection of early subclinical lung disease in children with cystic fibrosis by lung ventilation imaging with hyperpolarised gas MRI  
*Thorax* 2017; 72: 760 - 762

**Rosenow T., Ramsey K., Turkovic L., Murray CP., Mok LC., Hall GL., Stick SM.**

Air trapping in early cystic fibrosis lung disease Does CT tell the full story?  
*Pediatric Pulmonology* 2017; 52: 1150 - 1156

Scholz O., Denecke T., Bottcher J., Schwarz C., Mentzel HJ., Streitparth F., Maurer MH., Pfeil A., Huppertz A., Mehl A., Staab D., Hamm B., Renz DM. MRI of cystic fibrosis lung manifestations: sequence evaluation and clinical outcome analysis *Clinical Radiology* 2017; 72: 754 - 763

Triantopoulou S., Tsapaki V. Does clinical indication play a role in CT radiation dose in pediatric patients? *Physica Medica-european Journal of Medical Physics* 2017; 41: 53 - 57

Veldhoen S., Weng AM., Knapp J., Kunz AS., Stab D., Wirth C., Segerer F., Hebestreit H., Malzahn U., Kostler H., Bley TA. Self-gated Non-Contrast-enhanced Functional Lung MR Imaging for Quantitative Ventilation Assessment in Patients with Cystic Fibrosis *Radiology* 2017; 283: 242 - 251

## Screening

Alshehri N., Eissa S., Balobaid L., Rahman AMA., Dasouki M., Zourob M. Electrochemical Immunosensors for the Rapid Screening of Cystic Fibrosis and Duchenne Muscular Dystrophy *Electroanalysis* 2017; 29: 1911 - 1917

Behar DM., Inbar O., Shteinberg M., Gur M., Mussaffi H., Shoseyov D., Ashkenazi M., Alkrinawi S., Bormans C., Hakim F., Mei-Zahav M., Cohen-Cymerknoh M., Dagan A., Prais D., Sarouk I., Stafler P., El Bar Aluma B., Akler G., et al Nationwide genetic analysis for molecularly unresolved cystic fibrosis patients in a multiethnic society: implications for preconception carrier screening *Molecular Genetics & Genomic Medicine* 2017; 5: 223 - 236

Leung DH., Heltshe SL., Borowitz D., Gelfond D., Kloster M., Heubi JE., Stalvey M., Ramsey BW. Effects of Diagnosis by Newborn Screening for Cystic Fibrosis on Weight and Length in the First Year of Life *JAMA Pediatrics* 2017; 171: 546 - 554

Sermet-Gaudelus I., Brouard J., Audrezet MP., Kohen LC., Weiss L., Wizia N., Vrielynck S., Llerena K., Le Bourgeois M., Deneuille E., Remus N., Nguyen-Khoa T., Raynal C., Roussey M., Girodon E. Management of infants whose diagnosis is inconclusive at neonatal screening for cystic fibrosis *Archives de Pediatrie* 2017; 24: 401 - 414

Sommerburg O., Stahl M., Hammermann J., Okun JG., Kulozik A., Hoffmann G., Mall M. Newborn Screening on Cystic Fibrosis in Germany: Comparison of the new Screening Protocol with an Alternative Protocol *Klinische Padiatrie* 2017; 229: 59 - 66

## Therapy

Aali M., Caldwell A., House K., Zhou J., Chappe V., Lehmann C. Iron chelation as novel treatment for lung inflammation in cystic fibrosis *Medical Hypotheses* 2017; 104: 86 - 88

Abidin NZ., Haq IJ., Gardner Al., Brodlie M. Ataluren in cystic fibrosis: development, clinical studies and where are we now? *Expert Opinion on Pharmacotherapy* 2017; 18: 1363 - 1371

Ayoub N., Thamboo A., Habib A., Nayak JV., Hwang PH. Determinants and outcomes of upfront surgery versus medical therapy for chronic rhinosinusitis in cystic fibrosis *International Forum of Allergy & Rhinology* 2017; 7: 450 - 458

Baravalle-Einaudi M., Dufeu N., Dupont C., Vecellio L., Delaisi B., Carsin A., Dubus JC. Vibrating-mesh nebulizer maintenance by CF patients: Results from a French survey *Pulmonary Pharmacology & Therapeutics* 2017; 44: 57 - 60

Chin M., Aaron SD., Bell SC. The treatment of the pulmonary and extrapulmonary manifestations of cystic fibrosis *Presse Medicale* 2017; 46: E139 - E164

Corcoran TE., Godovchik JE., Donn KH., Busick DR., Goralski J., Locke LW., Markovetz MR., Myerburg MM., Muthukrishnan A., Weber L., Lacy RT., Pilewski JM. Overnight delivery of hypertonic saline by nasal cannula aerosol for cystic fibrosis *Pediatric Pulmonology* 2017; 52: 1142 - 1149

Corti A., Griese M., Hector A., Pompella A. Increasing sputum levels of gamma-glutamyltransferase may identify cystic fibrosis patients who do not benefit from inhaled glutathione *Journal of Cystic Fibrosis* 2017; 16: 342 - 345

De Boeck K., Haarman E., Hull J., Lands LC., Moeller A., Munck A., Riethmueller J., Tiddens H., Volpi S., Leadbetter J., Charlton B., Malfroot A. Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial *Journal of Cystic Fibrosis* 2017; 16: 380 - 387

Di Lullo AM., Scorza M., Amato F., Comegna M., Raia V., Maiuri L., Ilardi G., Cantone E., Castaldo G., Iengo M. An "ex vivo model" contributing to the diagnosis and evaluation of new drugs in cystic fibrosis *Acta Otorhinolaryngologica Italica* 2017; 37: 207 - 213

Donaldson SH., Solomon GM., Zeitlin PL., Flume PA., Casey A., McCoy K., Zemanick ET., Mandagere A., Troha JM., Shoemaker SA., Chmiel JF., Taylor-Cousar JL. Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR *Journal of Cystic Fibrosis* 2017; 16: 371 - 379

Edgeworth D., Keating D., Ellis M., Button B., Williams E., Clark D., Tierney A., Heritier S., Kotsimbos T., Wilson J. Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment *Clinical Science* 2017; 131: 2037 - 2045

Ermund A., Recktenwald CV., Skjak-Braek G., Meiss LN., Onsoyen E., Rye PD., Dessen A., Myrset AH., Hansson GC. OligoG CF-5/20 normalizes cystic fibrosis mucus by chelating calcium *Clinical and Experimental Pharmacology and Physiology* 2017; 44: 639 - 647

Fajac I., Wainwright CE. New treatments targeting the basic defects in cystic fibrosis *Presse Medicale* 2017; 46: E165 - E175

Ferreira ACM., Marson FAL., Cohen MA., Bertuzzo CS., Levy CE., Ribeiro AF., Ribeiro JD. Hypertonic Saline as a Useful Tool for Sputum Induction and Pathogen Detection in Cystic Fibrosis *Lung* 2017; 195: 431 - 439

Guichard MJ., Patil HP., Koussoroplis SJ., Wattiez R., Leal T., Vanbever R. Production and characterization of a PEGylated derivative of recombinant human deoxyribonuclease I for cystic fibrosis therapy *International Journal of Pharmaceutics* 2017; 524: 159 - 167

- Harbeson SL., Morgan AJ., Liu JF., Aslanian AM., Nguyen S., Bridson GW., Brummel CL., Wu LJ., Tung RD., Pilja L., Braman V., Uttamsingh V. Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development  
*Journal of Pharmacology and Experimental Therapeutics* 2017; 362: 359 - 367
- Hubert D., Chiron R., Camara B., Grenet D., Prevotat A., Bassinet L., Dominique S., Rault G., Macey J., Honore I., Kanaan R., Leroy S., Dufeu ND., Burgel PR. Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease  
*Journal of Cystic Fibrosis* 2017; 16: 388 - 391
- Ihrig V., Obermann WMJ. Identifying Inhibitors of the Hsp90-Ahal Protein Complex, a Potential Target to Drug Cystic Fibrosis, by Alpha Technology  
*SLAS Discovery* 2017; 22: 923 - 928
- Jaiswal N., Singh M., Agarwal A., Thumbaru KK. Palliative drug treatments for breathlessness in cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2017; : 8:CD011855
- Kua KP., Lee SWH. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis  
*Pharmacotherapy* 2017; 37: 755 - 769
- McKinzie CJ., Goralski JL., Noah TL., Retsch-Bogart GZ., Prieur MB. Worsening anxiety and depression after initiation of lumacaftor/ivacaftor combination therapy in adolescent females with cystic fibrosis  
*Journal of Cystic Fibrosis* 2017; 16: 525 - 527
- Molinski SV., Ahmadi S., Ip W., Ouyang H., Villella A., Miller JP., Lee PS., Kulleperuma K., Du K., Di Paola M., Eckford PDW., Laselva O., Huan LJ., Wellhauser L., Li E., Ray PN., Pomes R., Moraes TJ., Gonska T., Ratjen F., Bear Orkambi (R) and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue  
*EMBO Molecular Medicine* 2017; 9: 1224 - 1243
- Nenna R., Midulla F., Lambiase C., De Castro G., Zicari AM., Indinnimeo L., Cimino G., Troiani P., Quattrucci S., Tancredi G. Effects of inhaled hypertonic (7%) saline on lung function test in preschool children with cystic fibrosis: results of a crossover, randomized clinical trial  
*Italian Journal of Pediatrics* 2017; 43: ArNo: 60
- O'Neill K., Moran F., Tunney MM., Elborn JS., Bradbury I., Downey DG., Rendall J., Bradley JM. Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomized crossover study  
*BMJ Open Respiratory Research* 2017; 4: 1:UNSP e000168
- Popowicz N., Wood J., Tai A., Morey S., Mulrennan S. Immediate effects of lumacaftor/ivacaftor administration on lung function in patients with severe cystic fibrosis lung disease  
*Journal of Cystic Fibrosis* 2017; 16: 392 - 394
- Ratjen F., Hug C., Marigowda G., Tian S., Huang XH., Stanojevic S., Milla CE., Robinson PD., Waltz D., Davies JC. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled, phase 3 trial  
*Lancet Respiratory Medicine* 2017; 5: 557 - 567
- Scott DW., Walker MP., Sesma J., Wu B., Stuhlmiller TJ., Sabater JR., Abraham WM., Crowder TM., Christensen DJ., Tarran R. SPX-101 Is a Novel Epithelial Sodium Channel-targeted Therapeutic for Cystic Fibrosis That Restores Mucus Transport  
*American Journal of Respiratory and Critical Care Medicine* 2017; 196: 734 - 744
- Shanthikumar S., Massie J. A Review of Treatments That Improve Cystic Fibrosis Transmembrane Conductance Regulator Function  
*Clinical Medicine Insights-therapeutics* 2017; 9: ArNo: UNSP 117
- Strang A., Fischer AJ., Chidekel A. Pseudomonas eradication and clinical effectiveness of Ivacaftor in four Hispanic patients with S549N  
*Pediatric Pulmonology* 2017; 52: E37 - E39
- van Koningsbruggen-Rietschel S., Rietschel E. Cystic fibrosis. Disease on the way to personalized therapy  
*Monatsschrift Kinderheilkunde* 2017; 165: 681 - 687
- Zarrilli F., Amato F., Morgillo CM., Pinto B., Santarpia G., Borbone N., D'Errico S., Catalanotti B., Piccialli G., Castaldo G., Oliviero G. Peptide Nucleic Acids as miRNA Target Protectors for the Treatment of Cystic Fibrosis  
*Molecules* 2017; 22: 7:1144

## Transplantation

- Burcham P., Sarzynski L., Khalfoun S., Novak KJ., Miller JC., Tumin D., Hayes D. Immunosuppression Drug Therapy in Lung Transplantation for Cystic Fibrosis  
*Pediatric Drugs* 2017; 19: 339 - 346
- Ramos KJ., Somayaji R., Lease ED., Goss CH., Aitken ML. Cystic fibrosis physicians' perspectives on the timing of referral for lung transplant evaluation: a survey of physicians in the United States  
*BMC Pulmonary Medicine* 2017; 17: ArNo: 21
- Stephenson AL., Sykes J., Berthiaume Y., Singer LG., Chaparro C., Aaron SD., Whitmore GA., Stanojevic S. A clinical tool to calculate post-transplant survival using pre-transplant clinical characteristics in adults with cystic fibrosis  
*Clinical Transplantation* 2017; 31: 6:e12950
- Wan XX., Liu WF., Zheng T., Park JM., Smith DE., Feng MR. Population pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant recipients with and without cystic fibrosis  
*Xenobiotica* 2017; 47: 697 - 704